[go: up one dir, main page]

WO2001017515A1 - Degradable polymers - Google Patents

Degradable polymers Download PDF

Info

Publication number
WO2001017515A1
WO2001017515A1 PCT/US2000/024232 US0024232W WO0117515A1 WO 2001017515 A1 WO2001017515 A1 WO 2001017515A1 US 0024232 W US0024232 W US 0024232W WO 0117515 A1 WO0117515 A1 WO 0117515A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
polymer
integer
polymers
groups
Prior art date
Application number
PCT/US2000/024232
Other languages
French (fr)
Inventor
Steven James Brocchini
Marie-Claude Dubois Clochard
Original Assignee
School Of Pharmacy, University Of London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by School Of Pharmacy, University Of London filed Critical School Of Pharmacy, University Of London
Priority to EP00961523A priority Critical patent/EP1210093A4/en
Priority to JP2001521306A priority patent/JP2003528939A/en
Priority to AU73464/00A priority patent/AU7346400A/en
Priority to US10/069,929 priority patent/US6828412B1/en
Publication of WO2001017515A1 publication Critical patent/WO2001017515A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/26—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from polyamines and polycarboxylic acids
    • C08G69/34—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from polyamines and polycarboxylic acids using polymerised unsaturated fatty acids

Definitions

  • the present invention is concerned with degradable polymers and the production of materials therefrom. These polymers and materials find utility in polymer therapeutics and pharmaceutical compositions for the treatment of disease. Background of the Invention
  • Polymer Therapeutics are developed for biomedical applications requiring physiologically soluble polymers and include biologically active polymers, polymer-drug conjugates, polymer-protein conjugates, and other covalent constructs of bioactive molecules.
  • An exemplary class of a polymer-drug conjugate is derived from copolymers of hydroxypropyl methacrylamide (HPMA) which have been extensively studied for the conjugation of cytotoxic drugs for cancer chemotherapy (Duncan R: Drug- polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs, 1992, 3, 175-210. Putnam D, Kopecek J: Polymer conjugates with anticancer activity.
  • PK-1 displayed reduced toxicity compared to free doxorubicin in the Phase I studies (Vasey P, Twelves C, Kaye S, Wilson P, Morrison R, Duncan R, Thomson A, Hilditch T, Murray T, Burtles S, Cassidy J: Phase I clinical and pharmacokinetic study of PKI (HPMA copolymer doxorubicin): first member of a new class of chemotherapeutic agents : drug-polymer conjugates. Clin. Cancer Res., 1999, 5, 83-94). The maximum tolerated dose of PK-1 was 320 mg/m 2 which is 4-5 times higher than the usual clinical dose of free doxorubicin.
  • the polymers used to develop Polymer Therapeutics may also be separately developed for other biomedical applications where the polymer can form aggregates such as polymeric micelles and complexes.
  • Another important set of medical applications include those that require the polymer be used as a material, rather than as a physiologically soluble molecule.
  • drug release matrices including microspheres and nanoparticles
  • hydrogels including injectable gels and viscious solutions
  • hybrid systems e.g. liposomes with conjugated poly(ethylene glycol) (PEG) on the outer surface
  • devices including rods, pellets, capsules, films, gels
  • Polymers are also clinically widely used as excipients in drug formulation.
  • biomedical polymers provide a broad technology platform for optimising the efficacy of an active therapeutic drug.
  • Covalent conjugation of a drug to a soluble, biocompatible polymer can result in improved efficacy of the drug.
  • polymer-drug conjugates exhibit this improvement for the following main reasons: (1 ) altered biodistribution, (2) prolonged circulation, (3) release of the drug in the proteolytic and acidic environment of the secondary lysosome after cellular uptake of the conjugate by pinocytosis and (4) more favourable physicochemical properties imparted to the drug due to the characteristics of large molecules (e.g. increased drug solubility in biological fluids).
  • EPR enhanced permeability and retention
  • albumin has been investigated as a protein used to conjugate a bioactive molecule (Balboni P, Minia A, Grossi M, Barbanti- Brodano G, Mattioli A, Fiume L: Activity of albumin conjugates of 5- fluorodeoxyuridine and cytosine arabinoside on poxviruses as a lysosomotropic antiviral chemotherapy. Nature, 1976, 264, 181-183. Trouet A, Masquelier M, Baurain R, Campaneere D: A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases as required for a lysosomotropic drug-carrier conjugate.
  • the major limitations for using a protein to conjugate a bioactive compound include the propensity for inducing immunogenicity and non-specific degradation of the protein in vivo, and denaturation and irreversible alteration of the protein during preparation of the conjugate.
  • transferrin which binds to the tranferrin receptor and thus have the potential to undergo receptor-mediated uptake
  • transferrin which binds to the tranferrin receptor and thus have the potential to undergo receptor-mediated uptake
  • transferrin-mitomycin C conjugate in HL60 cells as a receptor- mediated drug targeting system.
  • various immuno-conjugates Gaal D, Hudecz F: Low toxicity and high antitumour activity of daunomycin by conjugation to an immunopotential amphoteric branced polypeptide.
  • transferrin which binds to the tranferrin receptor and thus have the potential to undergo receptor-mediated uptake
  • transferrin-mitomycin C conjugate in HL60 cells as a receptor- mediated drug targeting system.
  • various immuno-conjugates Gaal D, Hudecz F: Low toxicity and high antitumour activity of daunomycin by conjugation to an immunopotential amphoteric branced polypeptide. Eur. J. Cancer
  • Trail P Willner D, Hellestrom K: Site-directed delivery of anthracyclines for the treatment of cancer. Drug Dev. Res., 1995, 34. 196-209. Eno-Amooquaye E, Searle F, Boden J, harma S, Burke P: Altered biodistribution of an antibody - enzyme conjugate modified with polyethylene glycol. Br. J. Cancer, 1996, 73. 1323-1327. Flanagan P, Duncan R, Subr V, Ulbrich K, Kopeckova P, Kopecek J: Evaluation antibody-[N-(2-hydroxypropyl)methacrylamide] copolymer conjugates as targetable drug-carriers. 2.
  • Monodisperse molecular weight distribution is often claimed to be a significant advantage for using proteins to conjugate drugs, but this can only be useful if a single species of the protein-drug conjugate can be reproducibly prepared on adequate scale which is stable on storage. This is generally not economically or technologically possible to achieve in practice.
  • degradable synthetic polymers developed for biomedical application, and specifically for conjugation applications which can address the limitations inherent in the use of natural polymers for these applications.
  • Synthetic polymers which have been prepared and studied that are potentially degradable include polymers derived from amino acids (e.g. poly(glutamic acid) , poly[ 5 N-(2-hydroxyethyl)-L-glutamine), ⁇ -poly(2- hydroxyethyl aspartamide), poly(L-glutamic acid) and polylysine). These polymers when prepared for conjugation applications that require physiological solubility do not degrade in vivo to any extent within a time period of 10-100 hours. Additionally polymers and copolymers including pseudo-poly(amino acids) (James K, Kohn J: Pseudo-poly(amino acid)s: Examples for synthetic materials derived from natural metabolites.
  • the three main parts of a polymer-drug conjugate (1 ) polymer, (2) linker and (3) conjugated drug all have defined biological function. Together these components produce a distinct profile of pharmacological, pharmacokinetic and physicochemical properties typical of polymer-drug conjugates.
  • the polymer is not a mere carrier for the pharmacologically active drug.
  • the properties of the polymer are directly responsible for defining the circulation half-life, rate of cellular uptake, minimising toxicity of potent cytotoxic drugs and imparting favourable physicochemical properties (e.g. increasing the solubility of lipophilic drugs).
  • Lysosomes also contain a vast array of hydrolytic enzymes including proteases, esterases, glycosidases, phosphates and nucleases. Drugs have been conjugated to polymers using conjugation linkers that degrade in the lysosome while remaining intact in the bloodstream. Since many drugs are not pharmacologically active while conjugated to a polymer, this results in drastically reduced toxicity compared to the free drug in circulation.
  • linkages have been used to covalently bind a drug to the polymeric carrier.
  • linkages include, amide, ester, hydrazide, urethane, carbonate, imine, hydroxyl, thioether, azo and C-C.
  • pendent chain linkers designed to be stable in the bloodstream, but degradable by lysosomal enzymes and thus able to release the drug intracellularly.
  • Acid-labile, pH dependent linkers which are designed to remain stable in plasma at neutral pH (7.4), but release drug intracellularly by hydrolysis in the more acidic environment of the endosome and lysosome (pH 5.5 to 6.5).
  • Peptide linkers have been shown to mediate lysosomotropic drug delivery (wherein the drug preferentially accumulates in the lysosome). It has become apparent that one of the successful methods of control of the rate and location of drug release from pendent chain polymers has occurred favourably when a drug is bound to the polymer backbone via a peptidyl side-chain.
  • Dilman, et al (Cancer res., 1988, 48, 6097-6102) have conjugated daunorubicin to the anti-T-cell monaclonal antibody T101 using a cis-aconityl group. The pH sensitivity of the linkage was confirmed.
  • a similar study using a monaclonal antibody conjugated to doxorubicin has been shown to suppress the growth of established tumour xenografts in nude mice (Yang and Ricefelt Proc. Natl. Acad. Sci., 1988, 85, 1189-1193).
  • GB 2,270,920 discloses a therapeutically useful alginate-bioactive agent conjugate, wherein the alginate and bioactive agent are connected covalently via an acid labile linkage, preferably a cis-aconityl group.
  • An advantage of conjugating a drug via an acid-labile linker is that free drug alone can be released from the pendent chain rather than amino acid or peptide drug derivatives which can occur with peptidyl linkers.
  • One object of the present invention is to provide pH dependant degradeable polymers.
  • a further object of the present invention is to provide biocompatible, degradable polymers that will hydrolytically degrade at faster rates at acidic pH values than at neutral pH values
  • a further object of the present invention is to provide degradable polymers that degrade in the endosome or lysosome, while enabling conjugation to a lysosomally labile bioactive agent.
  • One embodiment of the invention provides a polymer comprising: a polymeric backbone comprising at least one unit having the structure (I),
  • R-R 4 comprise groups selected from the group consisting of H, C r C 12 alkyl, C 6 -C 18 aryl, C 7 -C 18 aralkyl, C 6 -C 18 cycloalkyl or any of the group consisting of C r C 12 alkyl, C 6 -C 18 aryl, C 7 -C 18 aralkyl, C 6 -C 18 cycloalkyl substituted, within the carbon chain or appended thereto, with one or more heteroatoms;
  • R and R 2 or R and R 4 or R and R 1 or R 2 and R 3 may be joined so that with the carbon atom(s) to which they are attached they together form a saturated, partially unsaturated or unsaturated ring system respectively, may have a pendent group which may incorporate a linker unit, (for example a peptide linkage) or a unit having the structure (I);
  • A comprises a proton donating moiety selected from the group consisting of
  • B comprises a hydrolytically labile group and is selected from the group consisting of
  • each R 5 is individually selected from the group consisting of H, 0,-0, 2 alkyl, C 6 -C 18 aryl, C 7 -C 18 aralkyl, C 6 -C 18 cycloalkyl; wherein groups A and B are in a cis-configuration about bond C a -C b ; m is an integer of 0 to 100, n, p and q are each an integer of 0 or 1 ; Q comprises 1 or more structures selected from the group consisting of
  • R 6 -R 11 are individually selected from the same group as defined for group R above and r is an integer between 1 and 5000, preferably 1 to 10, most preferably 1 to 6.
  • C a -C b may be a double bond, in which case p and q are 0 and groups A and B are in a cis-configuration across the double bond.
  • R and R 2 or R and R 4 or R and R 1 or R 2 and R 3 , preferably R and R 2 may be joined to oneanother to form part of a C 3 - C 12 ring system which may have none one or more than one unsaturated bond and may be aromatic.
  • a and B are in a cis- configuration about bond C a -C b .
  • a ring system is a C 3 -C 7 ring system
  • the ring system may incorporate any of the groups defined for R or may include one or more Q groups.
  • C a -C b is a single bond
  • p and q are 1 and R
  • R 1 , R 4 and A are selected from sterically bulky groups in such a way as to maintain a cis- configuration of A and B about bond C a -C b .
  • C a -C b is a double bond.
  • R-R 4 are individually selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl and hexyl and isomers thereof, acyl, alkoxy and acyloxy or mixtures thereof. Most preferably R, R 2 and R 3 are hydrogen.
  • each R 5 is individually selected from the group consisting of H, methyl, ethyl, propyl, butyl, pentyl and hexyl, preferably hydrogen.
  • A preferably comprises a group or a protected carboxylic acid group.
  • B preferably comprises an amide bond, and is most preferably a wherein R 5 has been hereinbefore defined.
  • Q may comprise more than one or a mixture of the structures defined above.
  • Q comprises a carbonyl group, -NR 12 -, -O- or -CH 2 - group, wherein R 12 is selected from the group consisting of hydrogen, C, .6 - alkyl, preferably methyl, ethyl, propyl, butyl, pentyl and hexyl and isomers thereof.
  • R 12 is a hydrogen atom.
  • Q comprises a carbonyl functionality or a -CH 2 - group, especially a carbonyl functionality.
  • bond C a -C b is a double bond
  • R is hydrogen
  • R 2 and R 3 are hydrogen
  • n is 1
  • m is 1
  • p and q are 0,
  • A is a carboxylic acid group
  • B comprises an amide bond
  • Q comprises an carbonyl group.
  • the groups A, B, Q, R-R 4 , m, n, p and q in each individual moiety are the same.
  • the other components of the polymeric backbone may be other groups having the structure (I), peptide units or other degradeable polymeric, oligomeric or monomeric units.
  • the polymeric backbone may comprise acrylic polymers, alkylene polymers, urethane polymers, amide polymers, polypeptides, polysaccharides and ester polymers.
  • the backbone components comprise derivatised polyethyleneglycol or copolymers of hydroxyalkyl(meth)acrylamide, most preferably amine derivatised polyethyleneglycol or hydroxypropylmethacrylamide-methacrylic acid copolymers, or derivatives thereof.
  • a further embodiment of the present invention provides a polymer comprising a polymeric backbone comprising the structure (II)
  • L is a polymeric, oligomeric or copolymeric bridging group which comprises groups selected from the group consisting of acrylic polymers, alkylene polymers, urethane polymers, polyethylene glycols, polyamides(including polypeptides).
  • polysaccharides and polyesters a is an integer of 1 to 100000, b and c are integers of 0 to 100000 and s is an integer of 0 to 100;
  • D comprises one or more structures individually selected from the group consisting of,
  • R 14 and R 14 ' comprise groups individually selected from the same groups as defined for Ror may comprise a structure selected from the group consisting of
  • n is an integer of 0-100
  • R 15 is selected from the group consisting of hydrogen and C C 6 alkyl
  • R 16 to R 18 are individually selected from the group consisting of H, C C 12 alkyl, C C 12 alkenyl, C 6 -C 18 aryl, C 7 -C 18 aralkyl, C 5 -C 18 cycloalkyl or is selected from the group consisting of C C 12 alkyl, C,-C 12 alkenyl, C 6 -C 18 aryl, C 7 -C 18 aralkyl, C 6 -C 18 cycloalkyl substituted, within the carbon chain or appended thereto, with one or more heteroatoms, a pendent group comprising a linker unit, for example a peptide linkage or a unit having the structure (I) or a leaving group;
  • R 13 is selected from the group consisting of H, C r C 12 alkyl, C r C 12 alkenyl, C 6 -C
  • L comprises a compound selected from the group comprising derivatised polyethyleneglycol and (hydroxyalkyl(meth)acrylamide-methacrylic acid copolymer or amide or ester derivative thereof, most preferably amine derivatised polyethyleneglycol.
  • L comprises a structure comprising a group selected from the group consisting of wherein PEG is polyethyleneglycol
  • R 19 -R 24 may be a pendent group comprising a cleavable linker unit, and comprise groups individually selected from the same groups as defined for R or may comprise a structure selected from the group consisting of
  • n and R 16 to R 18 have been defined hereinbefore.
  • s is preferably an integer of 1 to 10.
  • L is a group incorporating one of groups R 19 to R 24 , b is preferably 0.
  • R 14 to R 24 should incorporate a pendent group.
  • a pendent group incorporates a cleavable bond.
  • R 14 to R 24 comprise a cleavable group (I) as hereinbefore defined, or a peptidic bond capable of being cleaved by lysosomal enzymes.
  • R 16 -R 18 are H, tosylate, Fmoc, halogen, methyl, ethyl, propyl, butyl, pentyl or isomers thereof.
  • a pendent group as defined hereinbefore may incorporate a bioactive agent to form a conjugate.
  • the bioactive agent is an anti-cancer agent, for example doxorubicin, daunomycin, taxol and the like. This permits both cleavage of the linker unit, thus releasing drug to the desired site, and biodegradation of the macromolecular carrier, thus reducing side effects associated with the difficulty of clearing such molecules from the system.
  • the molecular weight of L is less than 220 kDa, more preferably less than 100 kDa, most preferably less than 30 kDa.
  • the polymer has a weight of 500D-400 kDa.
  • a further embodiment of the invention provides prepolymer comprising the structure (III)
  • A, B, Q, R-R 4 , R 13 , L, m, n, p and q are as defined herein before;
  • A', B', Q' R 1 '-R 4 ', m', n', p', and q' are selected from the groups as defined for A, B, Q, R 1 - R 4 m, n, p and q respectively;
  • E and K are selected from the group consisting of hydrogen, a protecting group or an activating group and may be the same or different;
  • z is an integer of of 1 to 100, y is an integer of 0 to 10 and x is an integer of 0 to 100.
  • z is preferably 1
  • y is preferably 1 or
  • x is preferably 1 or 0.
  • B and/or B' comprise a carboxylic acid group
  • E and K are an activating group selected from the group consisting of N- succinimidyl, pentachlorophenyl, pentaflourophenyl, para-nitrophenyl, dinitrophenyl, N-phthalimido, N-norbornyl, cyanomethyl, pyridyl, trichlorotriazine, 5-chloroquinolino.
  • groups E and K are known as an "active esters ".
  • E and K are N-succinimidyl.
  • activating moieties that can act as an acylation reagent, such as the mixed anhydrides.
  • A, B, Q, R-R 4 , D, m, n, p and q are as defined above, G and M are selected from the group consisting of hydrogen, an activating group or a protecting group and may be the same or different, i and j are integers of 1 to 10. i is preferably 1 and j is preferably 1.
  • G and M are an activating group as defined above.
  • G and M are hydrogen or N-succinimidyl.
  • a further embodiment provides process for preparing a polymer, copolymer or prepolymer comprising reacting at least one compound having the structure (V)
  • R 25 , R 26 and R 27 are selected from the group as defined for R;
  • Q" is selected from the group consisting of carboxylic acid, primary or secondary amine and carbonyl;
  • u is an integer of 0 or 1 ,
  • v is an integer of 1 to 100,
  • R 27 and R 25 may be attached to form part of a C 3 - C 12 ring system which may have more than one unsaturated bond and may be aromatic; with at least one compound selected from the group consisting of J and R 13 LNHR 28 , wherein L and R 13 groups are as defined above and R 28 is selected from the same group as defined for R and may be the same or different,
  • J is a compound having at least one primary or secondary amine and a carboxylic acid group and a pendent group incorporating a cleavable bond.
  • Q is a carboxylic acid group
  • R 27 is hydrogen
  • u and v are 1
  • R 25 and R 26 are hydrogen or methyl.
  • R 13 LNHR 28 comprises a NHR 29 group, wherein R 29 is individually selected from the same group as defined for R 28 .
  • a further embodiment provides a method of selectively degrading a polymer comprising the steps of: a) introducing a polymer as defined by structure (i) or (II) to an environment having a pH of less than 6.5, b) cleaving said polymer.
  • a further embodiment provides a method for releasing a bioactive agent comprising the steps of a) introducing a conjugate as described hereinbefore to an environment having a pH of less than 6.5, c) cleaving the bioactive agent from the linker group by acid or enzymic hydrolysis, d) optionally additionally cleaving the polymer by acid or enzymic hydrolysis.
  • compositions which comprise at least one polymer or polymer-bioactive agent conjugate and a carrier.
  • compositions may be administered orally, by injection, or topically and may comprise a pharmaceutically acceptable excipient.
  • a further embodiment of the invention includes the use of the novel polymer as a pharmaceutical excipient. As it degrades very quickly at low pH ranges it has application as an excipient for drug formulations prepared for oral administration (i.e. for rapid degradation in the gut or gastro intestinal tract where there are regions of very low pH).
  • novel polymers of the present invention may be water soluble or insoluble depending on size and the nature of its components.
  • the degradation products of the polymer are preferably soluble.
  • the present invention provides a polymer comprising an acid labile, pH dependent backbone incorporating a cis- aconityl group therein, more specifically a group having the structure (VI).
  • This group is designed to remain stable in plasma at neutral pH (-7.4), but degrade intracellularly by hydrolysis in the more acidic environment of the endosome or lysosome ( ⁇ pH 5.5 - 6.5).
  • the group (vi) is incorporated into a polymer backbone comprising a polymeric, oligomeric or copolymeric group which comprises functionalised or unfunctionalised polyethyleneglycol, ethyleneglycol copolymers, poly(hydroxyalkyl(meth)acrylamide), for instance hydroxypropylmethacrylamide-methacrylic acid copolymer (or amide or ester derivative thereof) and copolymers of styrene and maleic anhydride, polyurethanes, polyalkylenes and polyamides or amino acid residues.
  • the polymeric backbone should incorporate a functionalised polyethyleneglycol (PEG) polymer or copolymer most preferably an amine functionalised PEG polymer.
  • PEG polyethyleneglycol
  • the molecular weight of the polymer of the present invention is in the range of 30-400 kDa, while the weight of the prepolymer (III) is preferably less than about 220 kDa in order to ensure that the degraded polymer subunits are cleared from the lysosome and the kidney glomerulus. Most preferably the polymer degradation products have a molecular weight in the range of 0.5 kDa-30 kDa.
  • One preferred polymer of the present invention is a water soluble polyamide having the formula 3 and is made by the general reaction scheme summarised below: wherein PEG is a polyethylene glycol group having a molecular weight in the range 500 Da-100kDa or derivative thereof and u is an integer in the range of 1-10000.
  • the preferred polymer may be prepared by a 2 step, and optionally 3 step process.
  • an equivalent of cis-aconitic anhydride, 1 is reacted with a compound containing two primary or secondary amine groups.
  • Suitable solvents include non-protic solvents including acetonitrile, dimethylformamide, dimethylsulphoxide, DMA, tetrahydrofuran, ethyl acetate, dioxane, acetone etc. Preferably acetonitrile is used.
  • the product is isolated by a suitable method such as solvent separation and the resultant macromonomer 2 is then used as a prepolymer for the production of the acid labile polymer backbone.
  • Macromonomer (2) may be reacted with two equivalents of an activating group as described hereinbefore (N-hydroxysuccinimide shown) to produce an active monomer.
  • an activating group as described hereinbefore (N-hydroxysuccinimide shown) to produce an active monomer.
  • the reason for this is that the unprotected carboxylic acid moieties would otherwise compete in the polymerization reaction, resulting in potential incomplete degradation of the polymer backbone. This situation could, however, be used in the production or enablement of cross-linking and gel formation.
  • compound 3_ is produced.
  • This compound (3) or compound 2 may then be reacted further with a compound R 13 LNHR 28 as defined hereinbefore.
  • R 3 LNHR 28 is simply a amine-difunctionalised PEG molecule.
  • Other compounds that are suitable for use as R 13 LNHR 28 are
  • R 19 -R 24 have been defined hereinbefore.
  • the above defined R 14 -R 19 groups contain a group that is capable of conjugation to a drug, or a precursor thereof, for example, the group R 19 -R 24 should preferably contain a primary or secondary amine.
  • Suitable methods of attaching a linker molecule or a drug to the polymer backbone are as follows:
  • x is a leaving group such as tosylate, Br and the like.
  • the conditions for the step to the final product 4 of the reaction are different than the first, and involve the use of a condensation or coupling reagent type of compound such as a carbodiimide (e.g. dicyclohexyl carbodiimide, diisopropylcarbodiimide, 1 -(3-dimethylaminopropyl)-3- ethylcarbodiimide, mixed anhydride reagents (e.g. 2-ethoxy-1- ethoxycarbonyl-1-1 , 2-dihydroquinoline, 2-isobutoxy-1-isobutoxycarbonyl-2, 2-dihydroquinoline, isobutyl chloroformate), phosphonium salts (e.g.
  • a condensation or coupling reagent type of compound such as a carbodiimide (e.g. dicyclohexyl carbodiimide, diisopropylcarbodiimide, 1 -(3-dimethylaminopropy
  • benzotriazole-l-yl-oxy-tris-(dimethylamino)- phosphoniumhexafluorophosphate (Castro's reagent), bromo-tris-pyrrolidino- phosphonium hexafluorophospate, benzotriazole-1-yl-oxy-tris-pyrrolidino- phosphonium hexafluorophosphate), uronium salts (e.g.
  • carbonates e.g. 1 ,1'- carbonyl-diimidazole, N,N'-disuccininimidyl carbonate.
  • the particularly preferred solvents and conditions for this reaction are that molecule 2 is allowed to react in acetonitrile (with DIPC and hydroxysuccinimide) to give the macromonomer 3.
  • the macromonomer 3 is isolated then allowed to react in aqueous carbonate (Na 2 CO 3 ) at pH 9, 24 h at ambient temperature to give the polymer such as 4.
  • Another particularly preferred embodiment of the present invention is the production of the water soluble polyamide having the formula 7 and is made by the general reaction scheme summarised below:
  • PEG is a polyethylene glycol group having a molecular weight in the range 500 Da-100kDa or derivative thereof, and v is an integer in the range of 1-10000.
  • the preferred polymer may be prepared by a 2 step, and optionally 3 step process. In the first step an equivalent of cis- aconitic anhydride, 1, is reacted with a compound containing an amine group and a carboxylic acid group (8) wherein R 33 is selected from the same group of compounds as defined for R 19 -R 24 .
  • Suitable solvents again include non-protic solvents, preferably acetonitrile.
  • Macromonomer (2) may be reacted with two equivalents of a protecting group (N-hydroxysuccinimide shown) to produce an active monomer. If protection is carried out as shown, compound 6_ is produced.
  • This compound (6) or compound 5 may then be reacted further with a compound R 13 LNHR 28 as defined hereinbefore.
  • R 13 LNHR 28 is simply a amine-difunctionalised PEG molecule.
  • Other compounds that are envisaged for use as R 13 LNHR 28 are as shown above.
  • Another embodiment of the present invention is the production of the water soluble polyamide having the formula H and is made by the general reaction scheme summarised below: wherein n is an integer of 1-10000.
  • X is a halogen, preferably bromine and PEG is polyethyleneglycol.
  • Dimethylanhydride is reacted with a suitable halogenating agent to produce a halogenated dimethylanhydride.
  • Diamino- PEG is reacted with the halogenated anhydride to produce the polymer.
  • Suitable solvents for this method again include non-protic solvents, preferably dichloromethane. Since there is the free carboxylate (C-4) there is an equilibrium with the zwitterionic structure 12.
  • N-bromosuccinimide is used as the brominating agent. Since there is the free carboxylate (C-4) there is an equilibrium with the zwitterionic structure 12.
  • Figure 1 shows the degradation study of the preferred polyamide 4 of the invention at pH 7.4, 5.5 and 2 in phosphate buffer at 37 C as described in the Examples.
  • Figure 2 shows a continued degradation profile for polyamide 4 over a
  • Figure 3 shows the red blood cell lysis assay incubated for 24 h; 0, indicates polyamide 4; ⁇ indicates positive control, poly(ethylene imine); LJ indicates negative control, dextran.
  • the decrease in lysis observed with increasing concentration of poly(ethylene imine) is due to the partial precipitation of haemoglobin with this polymeric control.
  • Figure 4 shows B16 F10 cell viability (cytotoxicity) assay;0 indicates polymer 4; ⁇ indicates positive control, polylysine;U indicates negative control, dextran.
  • Figure 5 shows the in vitro degradation profile for poly(amido amine)
  • a 50 ml three neck round bottom flask was fitted with a condenser, thermometer and a dropping funnel.
  • the flask was cooled using a water ice bath and PEG NH2 500 Jeffamine (1.6 g, 3.2 mmol, 1 eq.) and acetonitrile (5.0 ml) were added to the flask.
  • PEG NH2 500 Jeffamine 1.6 g, 3.2 mmol, 1 eq.
  • acetonitrile 5.0 ml
  • To the dropping funnel was added c/s-aconitic anhydride 1 (2.0 g, 12.8 mmol, 4.0 eq.) and acetonitrile (10 ml). Under nitrogen atmosphere, the c/s-aconitic anhydride solution was slowly added over a 30 minute period to the Jeffamine solution which turned a light yellow coiour during the addition.
  • the reaction was exothermic and the risk of possible decarboxylation was minimised by ensuring that the temperature of the reaction mixture remained in the range of 0-3 °C through out the addition of the anhydride solution.
  • the ice water bath was the removed and the reaction mixture allowed to stir for 1 hour at ambient temperature.
  • Diethyl ether (30 ml) was then added to the solution and the reaction mixture poured into a separatory funnel. More ether was added and the macromonomer 2 separated as an oil which settled to the bottom of the separatory funnel and was isolated. Excess solvent was first evaporated from the crude macromononer 2 under flowing nitrogen and then the oil dried in vacuum at 40 °C. Preparation of polyamide 4.
  • PEG NH2 3400 (5,00g, 1.47 mmol, 1eq.) was dissolved in acetonitrile (35 ml) in a 100 ml round bottomed flask, placed in an argon atmosphere and kept cold by an ice bath. A two-fold excess of c/s-aconitic anhydride (0.92g, 5.88 mmol, 4eq) was dissolved in acetonitrile (5 ml) under argon atmosphere. C/s- aconitic anhydride solution was slowly added into the cold solution of PEG NH2 3400 over an hour, ensuring that addition was slow enough not to cause a colour change in the reaction mixture. The reaction was left to stir in the fridge overnight.
  • the macromonomer was precipitated from the solution with about three times the volume of chilled diethyl ether (120 ml). The precipitate was filtered with vacuum using a glass filter (porosity 3) and further dried in a dissector in vacuum for 30 minutes. The macromonomer 2 was obtained with an isolated yield of 88.1 %.
  • the IR and 1 H NMR data for macromonomer 2 is as follows:
  • the macromonomer 2 (2.00g, 0.54 mmol, 1 eq) was dissolved in acetonitrile (25 ml) in a 100 ml round bottom flask, placed in an argon atmosphere and kept cold with an ice bath. A two-fold excess for N- hydroxysuccinimide (NHS) (0.25g, 2.16 mmol, 4 eq.) was dissolved in acetonitrile (2 ml) and added to the cold macromonomer solution. Diisopropyl carbodiimide (DIPC) (0.14g, 1.08 mmol, 2 eq) was also dissolved in acetonitril (2 ml) and slowly added into the reaction solution.
  • DIPC Diisopropyl carbodiimide
  • the reactions was stirred overnight in the fridge. More acetonitrile (25 ml) was added the next day to dissolve the Diisopropyl urea DIPC precipitate that had been formed during the reaction.
  • the activated macromonomer 3 was then precipitated from the solution with about five times the volume of diethyl ether (250 ml) pre-chilled in an ice bath. The precipitate was filtered with vacuum using a glass filter (porosity 3) and further dried in a dissector in vacuum for 30 minutes. The activated macromonomer 3 was obtained with an isolated yield of 78.5%.
  • the IR and 1 H NMR data for activated macromonomer 3 is as follows:
  • PEG NH2 3'400 (0.7g, 0.20 mmol) was dissolved in pH 9 sodium carbonate solution (17 ml). The resultant solution was added to the activated macromonomer 3 (0.80g, 0.20 mmol) which had been weighted out in a 50 ml round bottom flask and placed in an ice bath. The pH of the final reaction mixture was checked with universal paper and adjusted slowly to pH 9 with sodium carbonate if necessary. The polymerisation was allowed to take place in the fridge. Aliquots were removed periodically and analysed by SEC to observe the conversion of polymerisation. After 25 hours, the polymer was precipitated into a chilled stirred solution of tetrahydrofuran (THF)-diethyl ether (2:3, 250 ml).
  • THF tetrahydrofuran
  • the precipitate was then filtered with vacuum using a glass filter (porosity 3) and further dried in a dissector in vacuum for 30 minutes.
  • the large polydispersity indicates that in the unfractionate or crude polymer mixture there was also some unreacted prepolymer, dimers, trimers and oligimers in addition to the desired 60 kDa material that was prepared.
  • the polymer 4 has also been prepared directly from the macromonomer 2 in organic solvent using a coupling reagent only without activating with N- hydroxysuccinimide.
  • the macromonmer 2 (2.00g, 0.54 mmol, 1 eq.) was dissolved in acetonitrile (25 ml) in a 100 ml round bottom flask, placed in an argon atmosphere and kept cold with an ice bath.
  • PEG NH2 3400 (1.83g, 0.54 mmol, 1 eq.) was dissolved in acetonitrile (25 ml) and added to the cold macromonomer solution.
  • DIPC (0.17 ml, 1.08 mmol, 2 eq.) was then slowly added and the polymerisation was allowed to take place in the fridge. Aliquots were removed periodically and analysed by SEC to observe the conversion of polymerisation.
  • the polymer was precipitated after 212 h with six times the volumes of ether (300 ml) pre-chilled in an ice bath. The precipitate was filtered under vacuum with glass filter (porosity 3) and further dried in a dissector under continuous vacuum for 30 minutes. Mw:..7O00 ⁇ 50'000 Da Degradation study.
  • biocompatibility assays are as follows: Cell Viability Assay. Adherent cells were seeded into separate, sterile, o flat-bottomed 96 well, tissue culture treated plates at a density of 5x10 4 cells/well
  • Red blood cell (RBC) lysis Fresh blood was obtained from male Wistar 5 rats (-250 g body weight) through cardiac puncture after carbon dioxide asphyxiation, and collected in a heparin/lithium blood tube. Erythrocytes were isolated by centrifugation (Heraeus Instruments, Varifuge 3.0RS) at 1530 ' g for 10 minutes at 4 °C. The supernatant was discarded along with the top 3-5 mm of the pellet. The erythrocytes were re-suspended in pH 7.4 phosphate buffer 0 solution (PBS) and the suspension was centrifuged as before and the supernatant was discarded. This washing process was repeated.
  • PBS pH 7.4 phosphate buffer 0 solution
  • a 2% w/v RBC suspension in PBS was then prepared.
  • Various concentrations of the polymers in PBS were added to 96-well plates, followed by the RBC suspension.
  • the negative control was dextran which does not cause haemolysis.
  • the positive 5 control was polyethylenimine (PEI) which causes RBC membranes to lyse.
  • the polymer concentrations tested were 0.75, 1.25, 2.5, 3.75 and 5 mg/ml.
  • the final volume in each well was 200 ml containing a 1 % w/v suspension of RBC.
  • Four wells were used for each concentration.
  • four wells were loaded with PBS instead of polymer as a negative control.
  • Eight wells on a separate plate 0 were loaded with 1 % v/v Triton-X 100 solution and RBC suspension to enable
  • Example 3 Synthesis of polyamide 7. o
  • the amino acid aconityl derivative 5 was synthesized from a reaction between c/s-aconitic anhydride 1 and Glycine 8.
  • Glycine 8 (1.299 g, 17.32 mmol) and 30 mL anhydrous acetonitrile were added to a 100 mL round bottom flask equipped with a magnetic stir bar and a pressure equilising dropping funnel.
  • Cis- Aconitic anhydride 1 4.322 g, 27.71 mmol
  • 10 mL anhydrous acetonitrile was added via the dropping funnel and the heterogeneous reaction mixture stirred at ambient temperature for 48 h.
  • the product 5 was filtered under vacuum with a glass filter (porosity 4), rinsed with chilled acetonitrile and dried in a dessicator in a vacuum and weighed to give an an isolated yield of 91 %.
  • the product 5 and was found to be soluble in water, methanol and ethanol.
  • the IR and 1 H NMR data for product 5 is as follows:
  • Amino acid aconityl derivative 5 (0.1 g, 0.433 mmol, 1 eq) and acetonitrile (5.0 ml) were placed into a 50 mL round bottom flask equipped with a magnetic stir bar and pressure equilising dropping funnel. The solution was cooled using a dry ice bath. Into another 50 mL round bottom flask equipped with a magnatic stirr bar was added pentachlorphenol (0.69 g, 2.598 mmol, 6 eq.) in anhydrous acetonitrile (10 ml). This solution was also cooled in an ice bath.
  • the activated monomer 6 obtained with an isolated yield of 62 %.
  • the activated monomer 6 0.2 g, 0.275 mmol, 1 eq
  • dichloromethane 10 ml
  • Polymer H is a poly(amido amine). Since there is the free carboxylate (C-4) there is an equilibrium with the zwitterionic structure 12.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polyamides (AREA)

Abstract

A polymer comprising: a polymeric backbone comprising at least one unit having the structure (I), wherein R-R4 comprise groups selected from the group consisting of H, C¿1?-C12 alkyl, C6-C18 aryl, C7-C18 aralkyl, C6-C18 cycloalkyl or any of the group consisting of C1-C12 alkyl, C6-C18 aryl, C7-C18 aralkyl, C6-C18 cycloalkyl substituted, within the carbon chain or appended thereto, with one or more heteroatoms; R and R?2¿ or R and R4 or R and R?1 or R2 and R3¿ may be joined so that with the carbon atom(s) to which they are attached they together form a saturated, partially unsaturated or unsaturated ring system respectively, may have a pendent group which may incorporate a linker unit, (for example a peptide linkage) or a unit having the structure (I); A comprises a proton donating moiety selected from the group consisting of formula (1). B comprises a hydrolytically labile group and is selected from the group consisting of formula (2), wherein each R5 is individually selected from the group consisting of H, C¿1?-C12 alkyl, C6-C18 aryl, C7-C18 aralkyl, C6-C18 cycloalkyl; wherein groups A and B are in a cis-configuration about bond Ca-Cb; m is an integer of 0 to 100, n, p and q are each an integer of 0 or 1; Q comprises 1 or more structures selected from the group consisting of formula (3) wherein R?6-R11¿ are individually selected from the same group as defined for group R above and r is an integer between 1 and 5000, preferably 1 to 10, most preferably 1 to 6; methods for the production, and uses thereof.

Description

Degradable Polymers
The present invention is concerned with degradable polymers and the production of materials therefrom. These polymers and materials find utility in polymer therapeutics and pharmaceutical compositions for the treatment of disease. Background of the Invention
Polymer Therapeutics (Duncan R., Polymer therapeutics for tumour specific delivery Chem & Ind 1997, 7, 262-264) are developed for biomedical applications requiring physiologically soluble polymers and include biologically active polymers, polymer-drug conjugates, polymer-protein conjugates, and other covalent constructs of bioactive molecules. An exemplary class of a polymer-drug conjugate is derived from copolymers of hydroxypropyl methacrylamide (HPMA) which have been extensively studied for the conjugation of cytotoxic drugs for cancer chemotherapy (Duncan R: Drug- polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs, 1992, 3, 175-210. Putnam D, Kopecek J: Polymer conjugates with anticancer activity. Adv.Polym.Sci., 1995, 122, 55-123. Duncan R, DimitrijevicS, Evagorou E: The role of polymer conjugates in the diagnosis and treatment of cancer. STP Pharma, 1996, 6, 237-263). An HPMA copolymer conjugated to doxorubicin known as PK-1 , is currently in Phase II evaluation in the UK. PK-1 displayed reduced toxicity compared to free doxorubicin in the Phase I studies (Vasey P, Twelves C, Kaye S, Wilson P, Morrison R, Duncan R, Thomson A, Hilditch T, Murray T, Burtles S, Cassidy J: Phase I clinical and pharmacokinetic study of PKI (HPMA copolymer doxorubicin): first member of a new class of chemotherapeutic agents : drug-polymer conjugates. Clin. Cancer Res., 1999, 5, 83-94). The maximum tolerated dose of PK-1 was 320 mg/m2 which is 4-5 times higher than the usual clinical dose of free doxorubicin.
The polymers used to develop Polymer Therapeutics may also be separately developed for other biomedical applications where the polymer can form aggregates such as polymeric micelles and complexes. Another important set of medical applications include those that require the polymer be used as a material, rather than as a physiologically soluble molecule. Thus, drug release matrices (including microspheres and nanoparticles), hydrogels (including injectable gels and viscious solutions) and hybrid systems (e.g. liposomes with conjugated poly(ethylene glycol) (PEG) on the outer surface) and devices (including rods, pellets, capsules, films, gels) can be fabricated for tissue or site specific drug delivery. Polymers are also clinically widely used as excipients in drug formulation. Within these three broad application areas: (1 ) physiologically soluble molecules, (2) materials and (3) excipients, biomedical polymers provide a broad technology platform for optimising the efficacy of an active therapeutic drug. Covalent conjugation of a drug to a soluble, biocompatible polymer can result in improved efficacy of the drug. Compared to the free, unconjugated drug, polymer-drug conjugates exhibit this improvement for the following main reasons: (1 ) altered biodistribution, (2) prolonged circulation, (3) release of the drug in the proteolytic and acidic environment of the secondary lysosome after cellular uptake of the conjugate by pinocytosis and (4) more favourable physicochemical properties imparted to the drug due to the characteristics of large molecules (e.g. increased drug solubility in biological fluids).
For the treatment of cancer there are marked improvements in therapeutic efficacy and site specific passive capture through the enhanced permeability and retention (EPR) effect. The EPR effect results from enhanced permeability of macromolecules or small particles within the tumour neovasculature due to leakiness of its discontinuous endothelium. In addition to the tumour angiogenesis (hypervasculature) and irregular and incompleteness of vascular networks, the attendant lack of lymphatic drainage promotes accumulation of macromolecules that extravasate. This effect is observed in many solid tumours for macromolecular agents and lipids. The enhanced vascular permeability will support the great demand of nutrients and oxygen for the rapid growth of the tumour. Unless specifically addressed for tumour cell uptake by receptor-medicated endocytosis, polymers entering the intratumoural environment are taken up relatively slowly by fluid-phase pinocytosis.
An increasing number of physiologically soluble polymers have been used as macromolecular partners for the conjugation of bioactive molecules. Many polymers have the disadvantage of being non-degradable in the polymer mainchain. For example, PEG (Monfardini C, Veronese F: Stabilization of substances in circulation. Bioconjugate Chem., 1998, 9, 418-450. Zalipsky S: Chemistry of polyethylene glycol conjugates with biologically active molecules. 5 Adv. Drug Delivery Rev., 1995, 16, 157-182. Delgado C, Francis G, Fisher D: The uses and properties of PEG-liked proteins. Crit. Rev. Ther. Drug Carrier Syst, 1992, 9, 249-304. Nucci M L, Shorr D, Abuchowski A: The therapeutic values of poly(ethylene glycol)-modified proteins. Adv. Drug Delivery Rev., 1991 , 6, 133-151. Nathan A, Zalipsky S, Ertel S, Agathos S, Yarmush M, Kohn 0 J: Copolymers of lysine and polyethylene glycol: A new family of functionalized drug carriers. Bioconjugate Chem., 1993, 4, 54-62) and HPMA (Putnam D, Kopecek J: Polymer conjugates with anticancer activity. Adv Polym.Sci., 1995, 122. 55-123. Duncan R, Dimitrijevic S, Evagorou E: The role of polymer conjugates in the diagnosis and treatment of cancer. STP Pharma, 1996, 6, 5 237-263) copolymers have been extensively studied for conjugation. PEG is also generally used in the pharmaceutical industry as a formulation excipient. These hydrophilic polymers are soluble in physiological media, but their main disadvantage is that the polymer mainchain does not degrade in vivo. Thus it is not possible to prohibit accumulation of these polymers in the body. Only o polymers with a molecular weight lower than the renal threshold can be used for systemic administration. It is imperative that for the systemic use of non- degradable polymers such as HPMA and PEG only molecules of a molecular weight which are readily cleared be administered or else long-term deleterious accumulation in healthy tissue will invariably result (Seymour L, Duncan R, 5 Strohalm J, Kopecek J: Effect of molecular weight (Mw) of N-(2- hydroxypropyl)methacrylamide copolymers on body distributions and rate of excretion after subcutaneous, intraperitoneal and intravenous administration to rats. J. Biomed. Mater. Res., 1987, 21, 1341-1358. Schneider P, Korolenko T, Busch U: A review of drug-induced lysosomal disorders of the liver in man and 0 laboratory animals. Microscopy Res. Tech., 1997, 36, 253-275. Hall C, Hall O:
Experimental hypertension elicited by injections of methyl cellulose. Experientia, 1961, 17, 544-454. Hall C, Hall O: Macromolecular hypertension: hypertensive cardiovascular disease from subcutaneously administered polyvinyl alcohol. Experientia, 1962, 18, 38-40).
Although some natural polymers such as polysaccharides have the advantage of being degradable in vivo, e.g. dextran, they typically lack a strict structural uniformity and have the propensity upon chemical modification (i.e. conjugation of a bioactive molecule) to become immunogenic or non-degradable (Vercauteren J, Bruneel D, Schacht E, Duncan R: Effect of the chemical modification of dextran on the degradation by dextranases. J. Bio. Comp. Polymers, 1990, 5, 4-15. Shalaby W, Park K: Chemical modification of proteins and polysaccharides and its effect on enzyme-catalysed degradation. In: Shalaby S, ed. Biomedical Polymers. Designed-to-degrade systems. New York: Hanser Publishers, 1994). Other polysaccharides which have been investigated for biomedical conjugation applications include chitosan (Ohya Y, Huang T, Ouchi T, Hasegawa K, Tamura J, Kadowaki K, Matsumoto T, Suzuki S: a-1 ,4- Polygalactosamine immobilised 5-fluorouracils through hexamethylene spacer groups via urea bonds. J. Cont. Rel., 1991, 17, 259-266), alginate (Al- Shamkhani A, Duncan R: Synthesis, controlled release properties and antitumour activity of alginate c/s-aconityl daunomycin conjugates. Int. J. Pharm., 1995, 122, 107-119. Morgan S, Al-Shamkhani A, Callant D, Schacht E, Woodley J, Duncan R: Alginates as drug carriers: covalent attachment of alginates to therapeutic agents containing primary amine groups. Int. J. Pharm.,
1995, 122, 121-128), hyaluronic acid (Schechter B, Neumann A, Wilchek M, Arnon R: Soluble polymers as carriers of cisplatinum. J. Cont. Rel., 1989, 10, 75-87), 6-O-carboxymethyl chitan (Ohya Y, Nonomura K, Ouchi T: In vivo and in vitro antitumor activity of CM-Chitin immobilized doxorubicins by lysosomal digestible tetrapeptide spacer groups. J. Bioact. Compat. Polymers, 1995, 10, 223-234) and 6-O-carboxymethyl pullulan (Nogusa H, Yano T, Okuno S, Hamana H, Inoue K: Synthesis of carboxymethylpullulan peptide doxorubicin conjugates and their properties. Chem. Pharm. Bull., 1995, 43, 1931-1936). Other natural polymers such as proteins can also be used to conjugate a bioactive molecule. For example albumin has been investigated as a protein used to conjugate a bioactive molecule (Balboni P, Minia A, Grossi M, Barbanti- Brodano G, Mattioli A, Fiume L: Activity of albumin conjugates of 5- fluorodeoxyuridine and cytosine arabinoside on poxviruses as a lysosomotropic antiviral chemotherapy. Nature, 1976, 264, 181-183. Trouet A, Masquelier M, Baurain R, Campaneere D: A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases as required for a lysosomotropic drug-carrier conjugate. In vitro and in vivo studies. Proc. Natl. Acad. Sci. USA, 1982, 7JL 626-629. Dosio F, Brusa P, Crosasso P, Arpicco S, LCattel: Preparation, characterization and properties in vitro and in vivo of a paclitaxel-albumin conjugate. J. Cont. Rel., 1997, 47(3), 293-304. Yasuzawa T, Tomer K: Structural determination of the conjugate of human serum albumin with a mitomycin C derivative, KW-2149, by matrix assisted laser desorption/ionization mass spectrometry. Bioconjugate Chem., 1997, 8, 391-399. Wunder A, Stehle G, Schrenk H, Hartung G, Heene D, Maier- Borst W, Sinn H: Antitumor activity of methotrexate-albumin conjugates in rats bearing a Walker-256 carcinoma. Int. J. Cancer, 1998, 76, 884-890). The major limitations for using a protein to conjugate a bioactive compound include the propensity for inducing immunogenicity and non-specific degradation of the protein in vivo, and denaturation and irreversible alteration of the protein during preparation of the conjugate. Other proteins such as transferrin, which binds to the tranferrin receptor and thus have the potential to undergo receptor-mediated uptake (Tanaka T, Kaneo Y, Miyashita M: Intracellular disposition and cytotoxicity of transferrin-mitomycin C conjugate in HL60 cells as a receptor- mediated drug targeting system. Biol. Pharm. Bull., 1998, 21(2), 147-152) and various immuno-conjugates (Gaal D, Hudecz F: Low toxicity and high antitumour activity of daunomycin by conjugation to an immunopotential amphoteric branced polypeptide. Eur. J. Cancer, 1998, 34(1 ). 155-16. Trail P, Willner D, Hellestrom K: Site-directed delivery of anthracyclines for the treatment of cancer. Drug Dev. Res., 1995, 34. 196-209. Eno-Amooquaye E, Searle F, Boden J, harma S, Burke P: Altered biodistribution of an antibody - enzyme conjugate modified with polyethylene glycol. Br. J. Cancer, 1996, 73. 1323-1327. Flanagan P, Duncan R, Subr V, Ulbrich K, Kopeckova P, Kopecek J: Evaluation antibody-[N-(2-hydroxypropyl)methacrylamide] copolymer conjugates as targetable drug-carriers. 2. Body distribution of anti Thy-1 ,2 antibody, anti-transferrin receptor antibody B3/25 and transferrin conjugates in DBA2 mice and activity of conjugates containing daunomycin against L1210 leukaemia in vivo. J. Cont. Rel., 1992, 18, 25-38. Springer C, Bagshawe K, Sharma S, Searle F, Boden J, Antoniw P, Burke P, Rogers G, Sherwood R, Melton R: Ablation of human choriocarcinoma xenografts in nude mice by antibody-directed enzyme prodrug therapy (ADEPT) with three novel compounds. Eur. J. Cancer, 1991 ,11, 1362-1366.) also have been investigated. Monodisperse molecular weight distribution is often claimed to be a significant advantage for using proteins to conjugate drugs, but this can only be useful if a single species of the protein-drug conjugate can be reproducibly prepared on adequate scale which is stable on storage. This is generally not economically or technologically possible to achieve in practice. Thus, there is a need for degradable synthetic polymers developed for biomedical application, and specifically for conjugation applications, which can address the limitations inherent in the use of natural polymers for these applications.
Synthetic polymers which have been prepared and studied that are potentially degradable include polymers derived from amino acids (e.g. poly(glutamic acid) , poly[5N-(2-hydroxyethyl)-L-glutamine), β-poly(2- hydroxyethyl aspartamide), poly(L-glutamic acid) and polylysine). These polymers when prepared for conjugation applications that require physiological solubility do not degrade in vivo to any extent within a time period of 10-100 hours. Additionally polymers and copolymers including pseudo-poly(amino acids) (James K, Kohn J: Pseudo-poly(amino acid)s: Examples for synthetic materials derived from natural metabolites. In: Park K, ed. Controlled Drug Delivery: Challenges and Strategies. Washington, DC: American Chemical Society, 1997; 389-403) and polyesters such as copolymers of polylactic and poly(glycolic acid), poly(α or β-malic acid) (Abdellaoui K, Boustta M, Vert M,
Morjani H, Manfait M: Metabolite-derived artificial polymers designed for drug targeting, cell penetration and bioresorption. Eur. J. Pharm. Sci., 1998, 6, 61-73. Ouchi T, Fujino A, Tanaka K, Banba T: Synthesis and antitumour activity of conjugates of poly (α-malic acid) and 5-fluorouracil bound via ester, amide or carbamoyl bonds. J. Cont. Rel., 1990, 12, 143-153), and block copolymers such as PEG-lysine (Nathan A, Zalipsky S, Ertel S, Agathos S, Yarmush M, Kohn J: Copolymers of lysine and polyethylene glycol: A new family of functionalized drug carriers. Bioconjugate Chem., 1993, 4, 54-62.), poly(lysine citramide) (Abdellaoui K, Boustta M, Vert M, Morjani H, Manfait M: Metabolite-derived artificial polymers designed for drug targeting, cell penetration and bicresorption. Eur. J. Pharm. Sci., 1998, 6, 61-73) and amino acid-PEG derived block copolymers (Kwon G, Kataoka K: Block copolymer micelles as long-circulating drug vehicles. Adv. Drug. Del. Rev., 1995, 16, 295-309. Alakhov V, Kabanov A: Block copolymeric biotransport carriers as versatile vehicles for drug delivery. Exp. Opin. Invest. Drugs, 1998, 7(9), 1453-1473) have also been investigated for conjugation.
The three main parts of a polymer-drug conjugate: (1 ) polymer, (2) linker and (3) conjugated drug all have defined biological function. Together these components produce a distinct profile of pharmacological, pharmacokinetic and physicochemical properties typical of polymer-drug conjugates. The polymer is not a mere carrier for the pharmacologically active drug. The properties of the polymer are directly responsible for defining the circulation half-life, rate of cellular uptake, minimising toxicity of potent cytotoxic drugs and imparting favourable physicochemical properties (e.g. increasing the solubility of lipophilic drugs).
Lysosomes also contain a vast array of hydrolytic enzymes including proteases, esterases, glycosidases, phosphates and nucleases. Drugs have been conjugated to polymers using conjugation linkers that degrade in the lysosome while remaining intact in the bloodstream. Since many drugs are not pharmacologically active while conjugated to a polymer, this results in drastically reduced toxicity compared to the free drug in circulation.
A wide variety of linkages have been used to covalently bind a drug to the polymeric carrier. Several examples include, amide, ester, hydrazide, urethane, carbonate, imine, hydroxyl, thioether, azo and C-C.
Following the concept of lysosomotropic drug delivery two broad classes of pendent chain linkers have emerged as the main focus of research over the last two decades. These are: 1. Peptidyl linkers designed to be stable in the bloodstream, but degradable by lysosomal enzymes and thus able to release the drug intracellularly. 2. Acid-labile, pH dependent linkers which are designed to remain stable in plasma at neutral pH (7.4), but release drug intracellularly by hydrolysis in the more acidic environment of the endosome and lysosome (pH 5.5 to 6.5).
Peptide linkers have been shown to mediate lysosomotropic drug delivery (wherein the drug preferentially accumulates in the lysosome). It has become apparent that one of the successful methods of control of the rate and location of drug release from pendent chain polymers has occurred favourably when a drug is bound to the polymer backbone via a peptidyl side-chain.
Since the discovery that peptidyl side chains in HPMA copolymers could be designed for cleavage by model enzymes such as chymotryspin, tryspin and papain recent studies have seen the systematic development of HPMA copolymer-anticancer conjugates. These contain peptidyl linkers tailored for cleavage by lysosomal proteases. Such linkers have now become more widely used in many different polymer conjugates. Shen and Ryser (Biochim, Biophys. Res. Commun., 1981 , 102, 1048-
1054) disclose pH-sensitive linkers of n-cis-aconityl and n-maleyl groups used to conjugate daunomycin to amino ethyl polyacrylamide and to poly(d- lysine). Hydrolysis of the cis-aconityl spacer released daunomycin from poly- (d-lysine) in the lysosomes. Diener, et al (Science, 1986, 231, 148-150) have shown that daunomycin, when conjugated to a targeting antigen by a cis-aconityl spacer, remains inactive in the extracellular system, but becomes active after cleavage within the acidic lysosomal environment of a target cell.
Dilman, et al (Cancer res., 1988, 48, 6097-6102) have conjugated daunorubicin to the anti-T-cell monaclonal antibody T101 using a cis-aconityl group. The pH sensitivity of the linkage was confirmed. A similar study using a monaclonal antibody conjugated to doxorubicin has been shown to suppress the growth of established tumour xenografts in nude mice (Yang and Ricefelt Proc. Natl. Acad. Sci., 1988, 85, 1189-1193). GB 2,270,920 discloses a therapeutically useful alginate-bioactive agent conjugate, wherein the alginate and bioactive agent are connected covalently via an acid labile linkage, preferably a cis-aconityl group.
An advantage of conjugating a drug via an acid-labile linker is that free drug alone can be released from the pendent chain rather than amino acid or peptide drug derivatives which can occur with peptidyl linkers.
The relatively low pH within the endosomal, and lysosomal compartments and the observation that the extracellular, interstitial environment in some tumours is also acidic, has inspired the development of pendent chain linkers that hydrolytically degrade more quickly at pH values less then 7.4. C/'s-aconityl acid and Schiff base derivatives are the two predominant types of hydrolytically labile linkers that have been explored.
One object of the present invention is to provide pH dependant degradeable polymers.
A further object of the present invention is to provide biocompatible, degradable polymers that will hydrolytically degrade at faster rates at acidic pH values than at neutral pH values
A further object of the present invention is to provide degradable polymers that degrade in the endosome or lysosome, while enabling conjugation to a lysosomally labile bioactive agent.
Summary of the Invention
One embodiment of the invention provides a polymer comprising: a polymeric backbone comprising at least one unit having the structure (I),
Figure imgf000011_0001
wherein R-R4 comprise groups selected from the group consisting of H, CrC12 alkyl, C6-C18 aryl, C7-C18 aralkyl, C6-C18 cycloalkyl or any of the group consisting of CrC12 alkyl, C6-C18 aryl, C7-C18 aralkyl, C6-C18 cycloalkyl substituted, within the carbon chain or appended thereto, with one or more heteroatoms; R and R2 or R and R4 or R and R1 or R2 and R3 may be joined so that with the carbon atom(s) to which they are attached they together form a saturated, partially unsaturated or unsaturated ring system respectively, may have a pendent group which may incorporate a linker unit, (for example a peptide linkage) or a unit having the structure (I); A comprises a proton donating moiety selected from the group consisting of
Figure imgf000012_0001
OH
0=S-OH 0=P-OH
B comprises a hydrolytically labile group and is selected from the group consisting of
Figure imgf000012_0002
wherein each R5 is individually selected from the group consisting of H, 0,-0,2 alkyl, C6-C18 aryl, C7-C18 aralkyl, C6-C18 cycloalkyl; wherein groups A and B are in a cis-configuration about bond Ca-Cb; m is an integer of 0 to 100, n, p and q are each an integer of 0 or 1 ; Q comprises 1 or more structures selected from the group consisting of
Figure imgf000012_0003
wherein R6-R11 are individually selected from the same group as defined for group R above and r is an integer between 1 and 5000, preferably 1 to 10, most preferably 1 to 6. Ca-Cb may be a double bond, in which case p and q are 0 and groups A and B are in a cis-configuration across the double bond. R and R2 or R and R4 or R and R1 or R2 and R3, preferably R and R2, may be joined to oneanother to form part of a C3 - C12 ring system which may have none one or more than one unsaturated bond and may be aromatic. When such a ring system is formed and Ca -Cb is not a double bond, A and B are in a cis- configuration about bond Ca -Cb. Preferably such a ring system is a C3-C7 ring system The ring system may incorporate any of the groups defined for R or may include one or more Q groups. When Ca -Cb is a single bond, p and q are 1 and R, R1, R4 and A are selected from sterically bulky groups in such a way as to maintain a cis- configuration of A and B about bond Ca -Cb. Preferably Ca-Cb is a double bond.
Preferably R-R4 are individually selected from the group consisting of hydrogen, methyl, ethyl, propyl, butyl, pentyl and hexyl and isomers thereof, acyl, alkoxy and acyloxy or mixtures thereof. Most preferably R, R2 and R3 are hydrogen.
Preferably each R5 is individually selected from the group consisting of H, methyl, ethyl, propyl, butyl, pentyl and hexyl, preferably hydrogen. A preferably comprises a group or a protected carboxylic acid group.
B preferably comprises an amide bond, and is most preferably a wherein R5 has been hereinbefore defined.
Figure imgf000013_0001
Q may comprise more than one or a mixture of the structures defined above. Preferably Q comprises a carbonyl group, -NR12-, -O- or -CH2- group, wherein R12 is selected from the group consisting of hydrogen, C,.6- alkyl, preferably methyl, ethyl, propyl, butyl, pentyl and hexyl and isomers thereof. Preferably R12 is a hydrogen atom.
Most preferably Q comprises a carbonyl functionality or a -CH2- group, especially a carbonyl functionality. In a particularly preferred embodiment bond Ca-Cb is a double bond, R is hydrogen, R2 and R3 are hydrogen, n is 1 , m is 1 , p and q are 0, A is a carboxylic acid group, B comprises an amide bond and Q comprises an carbonyl group.
Preferably where the polymer contains more than one (I) moiety, the groups A, B, Q, R-R4, m, n, p and q in each individual moiety are the same.
The other components of the polymeric backbone may be other groups having the structure (I), peptide units or other degradeable polymeric, oligomeric or monomeric units. For example, the polymeric backbone may comprise acrylic polymers, alkylene polymers, urethane polymers, amide polymers, polypeptides, polysaccharides and ester polymers. Preferably the backbone components comprise derivatised polyethyleneglycol or copolymers of hydroxyalkyl(meth)acrylamide, most preferably amine derivatised polyethyleneglycol or hydroxypropylmethacrylamide-methacrylic acid copolymers, or derivatives thereof.
A further embodiment of the present invention provides a polymer comprising a polymeric backbone comprising the structure (II)
Figure imgf000014_0001
wherein A, B, Q, R-R4, m, n, p and q are as defined above; L is a polymeric, oligomeric or copolymeric bridging group which comprises groups selected from the group consisting of acrylic polymers, alkylene polymers, urethane polymers, polyethylene glycols, polyamides(including polypeptides). polysaccharides and polyesters, a is an integer of 1 to 100000, b and c are integers of 0 to 100000 and s is an integer of 0 to 100; D comprises one or more structures individually selected from the group consisting of,
Figure imgf000015_0001
wherein R14 and R14' comprise groups individually selected from the same groups as defined for Ror may comprise a structure selected from the group consisting of
Figure imgf000015_0002
wherein n is an integer of 0-100, R15 is selected from the group consisting of hydrogen and C C6 alkyl, R16 to R18 are individually selected from the group consisting of H, C C12 alkyl, C C12 alkenyl, C6-C18 aryl, C7-C18 aralkyl, C5-C18 cycloalkyl or is selected from the group consisting of C C12 alkyl, C,-C12 alkenyl, C6-C18 aryl, C7-C18 aralkyl, C6-C18 cycloalkyl substituted, within the carbon chain or appended thereto, with one or more heteroatoms, a pendent group comprising a linker unit, for example a peptide linkage or a unit having the structure (I) or a leaving group; R13 is selected from the group consisting of H, CrC12 alkyl, CrC12 alkenyl, C6-C18 aryl, C7-C18 aralkyl, C5-C18 cycloalkyl or is selected from the group consisting of C,-C12 alkyl, C,-C12 alkenyl, C6-C18 aryl, C7-C18 aralkyl, C6-C18 cycloalkyl substituted, within the carbon chain or appended thereto, with one or more heteroatoms, R13 may contain a linker unit, for example a peptide linkage or a unit having the structure (I). Preferably L comprises a compound selected from the group comprising derivatised polyethyleneglycol and (hydroxyalkyl(meth)acrylamide-methacrylic acid copolymer or amide or ester derivative thereof, most preferably amine derivatised polyethyleneglycol.
Most preferably L comprises a structure comprising a group selected from the group consisting of
Figure imgf000016_0001
wherein PEG is polyethyleneglycol, R19-R24 may be a pendent group comprising a cleavable linker unit, and comprise groups individually selected from the same groups as defined for R or may comprise a structure selected from the group consisting of
Figure imgf000016_0002
wherein n and R16 to R18 have been defined hereinbefore. s is preferably an integer of 1 to 10.
Where L is a group incorporating one of groups R19 to R24, b is preferably 0.
Preferably at least one of R14 to R24 should incorporate a pendent group. Preferably such a pendent group incorporates a cleavable bond. This would be the case wherein R14 to R24 comprise a cleavable group (I) as hereinbefore defined, or a peptidic bond capable of being cleaved by lysosomal enzymes.
Preferably R16-R18 are H, tosylate, Fmoc, halogen, methyl, ethyl, propyl, butyl, pentyl or isomers thereof.
A pendent group as defined hereinbefore may incorporate a bioactive agent to form a conjugate. Preferably the bioactive agent is an anti-cancer agent, for example doxorubicin, daunomycin, taxol and the like. This permits both cleavage of the linker unit, thus releasing drug to the desired site, and biodegradation of the macromolecular carrier, thus reducing side effects associated with the difficulty of clearing such molecules from the system.
Preferably the molecular weight of L is less than 220 kDa, more preferably less than 100 kDa, most preferably less than 30 kDa. Preferably the polymer has a weight of 500D-400 kDa.
A further embodiment of the invention provides prepolymer comprising the structure (III)
(III)
Figure imgf000017_0001
wherein A, B, Q, R-R4, R13, L, m, n, p and q are as defined herein before; A', B', Q' R1'-R4', m', n', p', and q' are selected from the groups as defined for A, B, Q, R1- R4 m, n, p and q respectively; E and K are selected from the group consisting of hydrogen, a protecting group or an activating group and may be the same or different; z is an integer of of 1 to 100, y is an integer of 0 to 10 and x is an integer of 0 to 100. z is preferably 1 , y is preferably 1 or 0, x is preferably 1 or 0. Most preferably x=z. Preferably B=B\ Q=Q', A=A', R1-R4=R1,-R4', m=m\ n=n\ p=p' and q=q'. Preferably when B and/or B' comprise a carboxylic acid group, E and K are an activating group selected from the group consisting of N- succinimidyl, pentachlorophenyl, pentaflourophenyl, para-nitrophenyl, dinitrophenyl, N-phthalimido, N-norbornyl, cyanomethyl, pyridyl, trichlorotriazine, 5-chloroquinolino. These groups are formed from the reaction with group B, with the following compounds N-hydroxysuccinimide, pentachlorophenyl, pentaflourophenyl, para-nitrophenyl, dinitrophenyl, N- hydroxyphthalimide, N-hydroxynorbornene, cyanomethyl, hydroxypyridine, trichlorotriazine, 5-chloro-8-hydroxy-quinoline respectively. In this embodiment, groups E and K are known as an "active esters ". Preferably E and K are N-succinimidyl. There are other activating moieties that can act as an acylation reagent, such as the mixed anhydrides. A further embodiment of the present invention provides a prepolymer comprising the structure (IV)
Figure imgf000018_0001
wherein A, B, Q, R-R4, D, m, n, p and q are as defined above, G and M are selected from the group consisting of hydrogen, an activating group or a protecting group and may be the same or different, i and j are integers of 1 to 10. i is preferably 1 and j is preferably 1.
Preferably when B and/or D comprise a carboxylic acid group, G and M are an activating group as defined above. Preferably G and M are hydrogen or N-succinimidyl.
A further embodiment provides process for preparing a polymer, copolymer or prepolymer comprising reacting at least one compound having the structure (V)
Figure imgf000018_0002
wherein R25, R26 and R27 are selected from the group as defined for R; Q" is selected from the group consisting of carboxylic acid, primary or secondary amine and carbonyl; u is an integer of 0 or 1 , v is an integer of 1 to 100, R27 and R25 may be attached to form part of a C3 - C12 ring system which may have more than one unsaturated bond and may be aromatic; with at least one compound selected from the group consisting of J and R13LNHR28, wherein L and R13 groups are as defined above and R28 is selected from the same group as defined for R and may be the same or different, J is a compound having at least one primary or secondary amine and a carboxylic acid group and a pendent group incorporating a cleavable bond.
Preferably Q" is a carboxylic acid group, R27 is hydrogen, u and v are 1 , R25 and R26 are hydrogen or methyl. Most preferably R13LNHR28 comprises a NHR29 group, wherein R29 is individually selected from the same group as defined for R28.
A further embodiment provides a method of selectively degrading a polymer comprising the steps of: a) introducing a polymer as defined by structure (i) or (II) to an environment having a pH of less than 6.5, b) cleaving said polymer.
A further embodiment provides a method for releasing a bioactive agent comprising the steps of a) introducing a conjugate as described hereinbefore to an environment having a pH of less than 6.5, c) cleaving the bioactive agent from the linker group by acid or enzymic hydrolysis, d) optionally additionally cleaving the polymer by acid or enzymic hydrolysis.
The present invention also comprises compositions which comprise at least one polymer or polymer-bioactive agent conjugate and a carrier. In the case of in vivo treatment it is envisaged that the compositions may be administered orally, by injection, or topically and may comprise a pharmaceutically acceptable excipient.
A further embodiment of the invention includes the use of the novel polymer as a pharmaceutical excipient. As it degrades very quickly at low pH ranges it has application as an excipient for drug formulations prepared for oral administration (i.e. for rapid degradation in the gut or gastro intestinal tract where there are regions of very low pH).
The novel polymers of the present invention may be water soluble or insoluble depending on size and the nature of its components. The degradation products of the polymer are preferably soluble.
Detailed Description of the Invention
In one embodiment, the present invention provides a polymer comprising an acid labile, pH dependent backbone incorporating a cis- aconityl group therein, more specifically a group having the structure (VI). This group is designed to remain stable in plasma at neutral pH (-7.4), but degrade intracellularly by hydrolysis in the more acidic environment of the endosome or lysosome (~pH 5.5 - 6.5).
Figure imgf000020_0001
Preferably the group (vi) is incorporated into a polymer backbone comprising a polymeric, oligomeric or copolymeric group which comprises functionalised or unfunctionalised polyethyleneglycol, ethyleneglycol copolymers, poly(hydroxyalkyl(meth)acrylamide), for instance hydroxypropylmethacrylamide-methacrylic acid copolymer (or amide or ester derivative thereof) and copolymers of styrene and maleic anhydride, polyurethanes, polyalkylenes and polyamides or amino acid residues. In a particularly preferred embodiment the polymeric backbone should incorporate a functionalised polyethyleneglycol (PEG) polymer or copolymer most preferably an amine functionalised PEG polymer.
The molecular weight of the polymer of the present invention is in the range of 30-400 kDa, while the weight of the prepolymer (III) is preferably less than about 220 kDa in order to ensure that the degraded polymer subunits are cleared from the lysosome and the kidney glomerulus. Most preferably the polymer degradation products have a molecular weight in the range of 0.5 kDa-30 kDa.
One preferred polymer of the present invention is a water soluble polyamide having the formula 3 and is made by the general reaction scheme summarised below:
Figure imgf000021_0001
wherein PEG is a polyethylene glycol group having a molecular weight in the range 500 Da-100kDa or derivative thereof and u is an integer in the range of 1-10000.
As shown above, the preferred polymer may be prepared by a 2 step, and optionally 3 step process. In the first step an equivalent of cis-aconitic anhydride, 1, is reacted with a compound containing two primary or secondary amine groups.
Suitable solvents include non-protic solvents including acetonitrile, dimethylformamide, dimethylsulphoxide, DMA, tetrahydrofuran, ethyl acetate, dioxane, acetone etc. Preferably acetonitrile is used. The product is isolated by a suitable method such as solvent separation and the resultant macromonomer 2 is then used as a prepolymer for the production of the acid labile polymer backbone.
Macromonomer (2) may be reacted with two equivalents of an activating group as described hereinbefore (N-hydroxysuccinimide shown) to produce an active monomer. The reason for this is that the unprotected carboxylic acid moieties would otherwise compete in the polymerization reaction, resulting in potential incomplete degradation of the polymer backbone. This situation could, however, be used in the production or enablement of cross-linking and gel formation. If protection is carried out as shown, compound 3_ is produced. This compound (3) or compound 2 may then be reacted further with a compound R13LNHR28 as defined hereinbefore. In the diagram shown, R 3 LNHR28 is simply a amine-difunctionalised PEG molecule. Other compounds that are suitable for use as R13 LNHR28 are
Figure imgf000022_0001
wherein R19-R24 have been defined hereinbefore. Preferably the above defined R14-R19 groups contain a group that is capable of conjugation to a drug, or a precursor thereof, for example, the group R19-R24 should preferably contain a primary or secondary amine.
Suitable methods of attaching a linker molecule or a drug to the polymer backbone are as follows:
Figure imgf000022_0002
(II) = polymer (II) as defined
Figure imgf000022_0003
Figure imgf000022_0004
DRUG
Figure imgf000022_0005
Figure imgf000022_0006
Wherein x is a leaving group such as tosylate, Br and the like.
The reaction of compound 2 or 3 results in one of the preferred polymers of the present invention, compound 4.
The conditions for the step to the final product 4 of the reaction are different than the first, and involve the use of a condensation or coupling reagent type of compound such as a carbodiimide (e.g. dicyclohexyl carbodiimide, diisopropylcarbodiimide, 1 -(3-dimethylaminopropyl)-3- ethylcarbodiimide, mixed anhydride reagents (e.g. 2-ethoxy-1- ethoxycarbonyl-1-1 , 2-dihydroquinoline, 2-isobutoxy-1-isobutoxycarbonyl-2, 2-dihydroquinoline, isobutyl chloroformate), phosphonium salts (e.g. benzotriazole-l-yl-oxy-tris-(dimethylamino)- phosphoniumhexafluorophosphate (Castro's reagent), bromo-tris-pyrrolidino- phosphonium hexafluorophospate, benzotriazole-1-yl-oxy-tris-pyrrolidino- phosphonium hexafluorophosphate), uronium salts (e.g. 2-(1H-benzotriazole- 1-yl)-1 ,2,3,3,-tetramethyluronium hexafluorophosphate, 2-(1 H-benzotriazole- 1-yl)-1 ,1 ,3,3,-tetramethyluronium tetrafluoroborate) and carbonates (e.g. 1 ,1'- carbonyl-diimidazole, N,N'-disuccininimidyl carbonate).
The particularly preferred solvents and conditions for this reaction are that molecule 2 is allowed to react in acetonitrile (with DIPC and hydroxysuccinimide) to give the macromonomer 3. The macromonomer 3 is isolated then allowed to react in aqueous carbonate (Na2CO3) at pH 9, 24 h at ambient temperature to give the polymer such as 4.
Another particularly preferred embodiment of the present invention is the production of the water soluble polyamide having the formula 7 and is made by the general reaction scheme summarised below:
Figure imgf000024_0001
wherein PEG is a polyethylene glycol group having a molecular weight in the range 500 Da-100kDa or derivative thereof, and v is an integer in the range of 1-10000. As with compound 4, the preferred polymer may be prepared by a 2 step, and optionally 3 step process. In the first step an equivalent of cis- aconitic anhydride, 1, is reacted with a compound containing an amine group and a carboxylic acid group (8) wherein R33 is selected from the same group of compounds as defined for R19-R24.
Suitable solvents again include non-protic solvents, preferably acetonitrile. Macromonomer (2) may be reacted with two equivalents of a protecting group (N-hydroxysuccinimide shown) to produce an active monomer. If protection is carried out as shown, compound 6_ is produced. This compound (6) or compound 5 may then be reacted further with a compound R13LNHR28 as defined hereinbefore. In the diagram shown, R13LNHR28 is simply a amine-difunctionalised PEG molecule. Other compounds that are envisaged for use as R13LNHR28 are as shown above.
Another embodiment of the present invention is the production of the water soluble polyamide having the formula H and is made by the general reaction scheme summarised below:
Figure imgf000025_0001
wherein n is an integer of 1-10000. X is a halogen, preferably bromine and PEG is polyethyleneglycol. Dimethylanhydride is reacted with a suitable halogenating agent to produce a halogenated dimethylanhydride. Diamino- PEG is reacted with the halogenated anhydride to produce the polymer.
Suitable solvents for this method again include non-protic solvents, preferably dichloromethane. Since there is the free carboxylate (C-4) there is an equilibrium with the zwitterionic structure 12.
A particular example of this reaction is shown below.
Figure imgf000025_0002
N-bromosuccinimide is used as the brominating agent. Since there is the free carboxylate (C-4) there is an equilibrium with the zwitterionic structure 12.
Brief description of the drawings:
The references in the figures to particular relates to the specific compounds exemplified in the examples below. Figure 1 shows the degradation study of the preferred polyamide 4 of the invention at pH 7.4, 5.5 and 2 in phosphate buffer at 37 C as described in the Examples.
Figure 2 shows a continued degradation profile for polyamide 4 over a
6 day period. Figure 3 shows the red blood cell lysis assay incubated for 24 h; 0, indicates polyamide 4; Δ indicates positive control, poly(ethylene imine); LJ indicates negative control, dextran. The decrease in lysis observed with increasing concentration of poly(ethylene imine) is due to the partial precipitation of haemoglobin with this polymeric control.
Figure 4 shows B16 F10 cell viability (cytotoxicity) assay;0 indicates polymer 4; Δ indicates positive control, polylysine;U indicates negative control, dextran. Figure 5 shows the in vitro degradation profile for poly(amido amine)
11 at pH 7.4, 6.5, 5.5 and 2.0. The procedure used to obtain this degradation profile was the same used to obtain the degradation profile for polyamide 4.
Examples It should be noted that the compounds exemplified throughout the examples below are referred to with reference numerals. The same reference numerals are used to refer to the more broadly defined compounds in the description above. The more specific definitions used in the examples below is not intended to restrict the broader definitions used throughout the description above.
Example 1
Preparation of Macromonomer 2.
A 50 ml three neck round bottom flask was fitted with a condenser, thermometer and a dropping funnel. The flask was cooled using a water ice bath and PEGNH2500 Jeffamine (1.6 g, 3.2 mmol, 1 eq.) and acetonitrile (5.0 ml) were added to the flask. To the dropping funnel was added c/s-aconitic anhydride 1 (2.0 g, 12.8 mmol, 4.0 eq.) and acetonitrile (10 ml). Under nitrogen atmosphere, the c/s-aconitic anhydride solution was slowly added over a 30 minute period to the Jeffamine solution which turned a light yellow coiour during the addition. The reaction was exothermic and the risk of possible decarboxylation was minimised by ensuring that the temperature of the reaction mixture remained in the range of 0-3 °C through out the addition of the anhydride solution. The ice water bath was the removed and the reaction mixture allowed to stir for 1 hour at ambient temperature. Diethyl ether (30 ml) was then added to the solution and the reaction mixture poured into a separatory funnel. More ether was added and the macromonomer 2 separated as an oil which settled to the bottom of the separatory funnel and was isolated. Excess solvent was first evaporated from the crude macromononer 2 under flowing nitrogen and then the oil dried in vacuum at 40 °C. Preparation of polyamide 4.
To a solution of macromonomer 2 (0.73 g, 0.913 mmol) and N- hydroxysuccinimide (0.21 g, 1.826 mmol) in methanol (15.0 ml) at 0 °C (cooled by ice water bath) was slowly added diisopropylcarbodiimide (0.38g , 1.826 mmol). The ice bath was removed and the red coloured reaction mixture stirred at ambient temperature for 2 h. Diethyl ether was then added to the reaction mixture to oil out the activated bis-NHS ester which was collected using a separatory funnel, and dried under flowing nitrogen and in vacuum (40 °C). A quantity of the bis-NHS diester 3 (0.25 g, 0.213 mmol) was then allowed to react with Jeffamine (0.11 g, 0.22 mmol) in an aqueous solution (10.0 ml) of NaCO3 (30.0 mg, 0.283 mmol) at ambient temperature. The reaction proceeded for 2 h while maintaining the pH at 9.0 (using NaCO3). THF (5.0 ml) was added to the reaction mixture and the solution transferred to a separatory funnel where the polyamide 4 separated out as an oil which was isolated and dried using flowing nitrogen and then in vacuum (40 °C). The yield of the polyamide 4 was about 40% and was further purified by again dissolving in water and adding THF to separate as an oil (Mw= 18,000 Da, PD=1.4 -1.6). Example 2
Preparation of macromonomer 2.
PEGNH23400 (5,00g, 1.47 mmol, 1eq.) was dissolved in acetonitrile (35 ml) in a 100 ml round bottomed flask, placed in an argon atmosphere and kept cold by an ice bath. A two-fold excess of c/s-aconitic anhydride (0.92g, 5.88 mmol, 4eq) was dissolved in acetonitrile (5 ml) under argon atmosphere. C/s- aconitic anhydride solution was slowly added into the cold solution of PEGNH23400 over an hour, ensuring that addition was slow enough not to cause a colour change in the reaction mixture. The reaction was left to stir in the fridge overnight. The macromonomer was precipitated from the solution with about three times the volume of chilled diethyl ether (120 ml). The precipitate was filtered with vacuum using a glass filter (porosity 3) and further dried in a dissector in vacuum for 30 minutes. The macromonomer 2 was obtained with an isolated yield of 88.1 %. The IR and 1H NMR data for macromonomer 2 is as follows:
FTIR (ATR) : 1715 cm"1 (s;COOH), 1636 cm"1 (s; CO-NH), 1544 cm"1 (s;C=C). 1H NMR (CD3OD) : d = 3.2 (q;-CH2-PEG-NH-C=O), 3.45 (s;-CH2), 3.65 (large s;H-PEG), 6.5 (s;vinylic H) Preparation of the activated macromonomer 3.
The macromonomer 2 (2.00g, 0.54 mmol, 1 eq) was dissolved in acetonitrile (25 ml) in a 100 ml round bottom flask, placed in an argon atmosphere and kept cold with an ice bath. A two-fold excess for N- hydroxysuccinimide (NHS) (0.25g, 2.16 mmol, 4 eq.) was dissolved in acetonitrile (2 ml) and added to the cold macromonomer solution. Diisopropyl carbodiimide (DIPC) (0.14g, 1.08 mmol, 2 eq) was also dissolved in acetonitril (2 ml) and slowly added into the reaction solution. The reactions was stirred overnight in the fridge. More acetonitrile (25 ml) was added the next day to dissolve the Diisopropyl urea DIPC precipitate that had been formed during the reaction. The activated macromonomer 3 was then precipitated from the solution with about five times the volume of diethyl ether (250 ml) pre-chilled in an ice bath. The precipitate was filtered with vacuum using a glass filter (porosity 3) and further dried in a dissector in vacuum for 30 minutes. The activated macromonomer 3 was obtained with an isolated yield of 78.5%. The IR and 1H NMR data for activated macromonomer 3 is as follows:
FTIR (ATR) : 1739 cm"1 (s;CO-O-N), 1716 cm"1 (s;COOH), 1667 cm"1 (s; CO-N- CO), 1638 cm"1 (s; CO-NH), 1544 cm"1 (s;C=C)
1H NMR (CD3OD) : d = 2.68 (s;H-NHS), 3.2 (q;-CH2 PEG-NH-C=O), 3.45 (s;-CH2) 3.65 (large s;H-PEG), 6.5 (s;vinylic H) Polymerisation of the activated macromonomer 3 and PEGNH23400 in aqueous solution.
PEGNH23'400 (0.7g, 0.20 mmol) was dissolved in pH 9 sodium carbonate solution (17 ml). The resultant solution was added to the activated macromonomer 3 (0.80g, 0.20 mmol) which had been weighted out in a 50 ml round bottom flask and placed in an ice bath. The pH of the final reaction mixture was checked with universal paper and adjusted slowly to pH 9 with sodium carbonate if necessary. The polymerisation was allowed to take place in the fridge. Aliquots were removed periodically and analysed by SEC to observe the conversion of polymerisation. After 25 hours, the polymer was precipitated into a chilled stirred solution of tetrahydrofuran (THF)-diethyl ether (2:3, 250 ml). The precipitate was then filtered with vacuum using a glass filter (porosity 3) and further dried in a dissector in vacuum for 30 minutes. MwSEC>60,000 Da (phosphate buffer solution mobile phase, PEG standards); large polydispersity. The large polydispersity indicates that in the unfractionate or crude polymer mixture there was also some unreacted prepolymer, dimers, trimers and oligimers in addition to the desired 60 kDa material that was prepared. The IR and 1H NMR data for the resultant polyamide 4 is as follows: FTIR (ATR) : 1701 cm"1 (s;COOH), 1647 cm"1 (s; CO-NH), 1540 cm"1 (s;C=C) 1H NMR (CD3OD) : d=3.2 (q;-CH2-PEG-NH-C=O), 3.45 (s;-CH2), 3.65 (large s;H- PEG), 6.5 (s;vinylic H)
The polymer 4 has also been prepared directly from the macromonomer 2 in organic solvent using a coupling reagent only without activating with N- hydroxysuccinimide.
Polymerisation of macromonomer 2 and PEGNH23400 in organic phase.
The macromonmer 2 (2.00g, 0.54 mmol, 1 eq.) was dissolved in acetonitrile (25 ml) in a 100 ml round bottom flask, placed in an argon atmosphere and kept cold with an ice bath. PEGNH23400 (1.83g, 0.54 mmol, 1 eq.) was dissolved in acetonitrile (25 ml) and added to the cold macromonomer solution. DIPC (0.17 ml, 1.08 mmol, 2 eq.) was then slowly added and the polymerisation was allowed to take place in the fridge. Aliquots were removed periodically and analysed by SEC to observe the conversion of polymerisation. The polymer was precipitated after 212 h with six times the volumes of ether (300 ml) pre-chilled in an ice bath. The precipitate was filtered under vacuum with glass filter (porosity 3) and further dried in a dissector under continuous vacuum for 30 minutes. Mw:..7O00<50'000 Da Degradation study.
An in vitro controlled degradation study at 5.5 and 7.4 was carried out on the polyamide 4 obtained via NHS activation. Degradation studies were performed over 7 days at 37°C. In addition, pH 2 was also used but only for 42 hours due to the rapid degradation of the polyamide. These three pH conditions were tested to demonstrate that the polyamides 4 displayed enhanced rates of degradation at acidic pH values. In particular, pH 7.4 and 5.5 were selected to simulate physiological conditions in the blood circulation and in cell lysosomes respectively. The experiment at pH 2 was selected to simulate the physiological conditions in the gastrointestinal tract. 5 Polyamide 4 and its degradation products were soluble in aqueous solution so direct comparisons of GPC peak intensities at each time point were used to help monitor the extent of degradation. The degradation profile of polyamide 4 at pH 5.5 and 2.0 displayed a rapid phase during the first 2-4 hours (Figure 1 ). A slower degradation phase then followed and was observed over a 0 6 day period (Figure 2). The rate of this second phase was faster at pH 2.0 and was monitored for only 41 hours at pH 2.0 because the decreasing intensity of the high molecularweight GPC peak could not unambiguously be discerned from the GPC trace of lower molecular weight material still remaining in solution. Throughout the degradation study there was a concomitant increase in GPC 5 intensities at lower molecular weights.
In vitro assays indicated polyamide 4 did not lyse red blood cells (Figure 3) nor was cytotoxic (Figure 4).
The procedures used for the biocompatibility assays are as follows: Cell Viability Assay. Adherent cells were seeded into separate, sterile, o flat-bottomed 96 well, tissue culture treated plates at a density of 5x104 cells/well
(B16 F10 cells at 1x104 cells/well). The culture was then left to incubate for 24 h in standard conditions. Prior to the end of the 24 h incubation period, the polymers to be assayed were dissolved in fresh culture medium. This was used to replace the existing media covering the cells after the designated incubation 5 period and concentrations between 0-5 mg/ml were used. The cultures were then incubated using standard conditions for 67 h. During this time, 250 mg of 3-[4,5-dimethylthiazol-2-yl]-2-5-diphenyltetrazollium bromide (MTT) was dissolved in 50 ml of PBS and filter sterilised. After the 67 h incubation, 20 μl of MTT stock was added to each well giving a final concentration of 833 μg/ml of o MTT in the media. The experiment was then left to incubate for a further 5 h again using standard conditions. After a further incubation period of 5 h the culture media was removed and 100 μl of optical grade DMSO was added to each well. The cultures were left for 1 h in DMSO and the plates were read at 550 nm using a microtitre plate reader. The results are shown in Figure 4 and are expressed as viability (%) (± standard deviation (S.D.)) against polymer concentration.
Red blood cell (RBC) lysis. Fresh blood was obtained from male Wistar 5 rats (-250 g body weight) through cardiac puncture after carbon dioxide asphyxiation, and collected in a heparin/lithium blood tube. Erythrocytes were isolated by centrifugation (Heraeus Instruments, Varifuge 3.0RS) at 1530 ' g for 10 minutes at 4 °C. The supernatant was discarded along with the top 3-5 mm of the pellet. The erythrocytes were re-suspended in pH 7.4 phosphate buffer 0 solution (PBS) and the suspension was centrifuged as before and the supernatant was discarded. This washing process was repeated. A 2% w/v RBC suspension in PBS was then prepared. Various concentrations of the polymers in PBS were added to 96-well plates, followed by the RBC suspension. The negative control was dextran which does not cause haemolysis. The positive 5 control was polyethylenimine (PEI) which causes RBC membranes to lyse. The polymer concentrations tested were 0.75, 1.25, 2.5, 3.75 and 5 mg/ml. The final volume in each well was 200 ml containing a 1 % w/v suspension of RBC. Four wells were used for each concentration. In addition, four wells were loaded with PBS instead of polymer as a negative control. Eight wells on a separate plate 0 were loaded with 1 % v/v Triton-X 100 solution and RBC suspension to enable
100 % haemoglobin release. The plates were incubated at 37 °C in a humidified environment, one set of plates for 1 h, and another set for 24 h. After the incubation period, the plates were centrifuged (1500 ' g, 10 min, 4 °C), and the supernatant transferred to wells on a clean plate. The UV absorbance (Titertek 5 Multiskan Plus) of the solution in each well was measured at 550 nm to assess the degree of RBC lysis relative to Triton-X 100. The results are shown in Figure 3.
Example 3 Synthesis of polyamide 7. o The amino acid aconityl derivative 5 was synthesized from a reaction between c/s-aconitic anhydride 1 and Glycine 8. Glycine 8 (1.299 g, 17.32 mmol) and 30 mL anhydrous acetonitrile were added to a 100 mL round bottom flask equipped with a magnetic stir bar and a pressure equilising dropping funnel. Cis- Aconitic anhydride 1 (4.322 g, 27.71 mmol) in 10 mL anhydrous acetonitrile was added via the dropping funnel and the heterogeneous reaction mixture stirred at ambient temperature for 48 h. The product 5 was filtered under vacuum with a glass filter (porosity 4), rinsed with chilled acetonitrile and dried in a dessicator in a vacuum and weighed to give an an isolated yield of 91 %. The product 5 and was found to be soluble in water, methanol and ethanol. The IR and 1H NMR data for product 5 is as follows:
FTIR (ATR) : 1713, 1696 cm'1 (s;COOH), 1634 cm'1 (s; CO-NH), 1521 cm'1 (s;C=C) 1H NMR (D2O) : d = 3.25 (s;CH2), 3.87 (s;CH2), 5.82 (s;vinylic H)
Combustion analysis: Calculated C: 41.57; H: 3.92; N:6.06. Found C: 41.34; H:
4.04; N:5.87.
Activation of monomer 5 to give a bis-active ester monomer 6.
Amino acid aconityl derivative 5 (0.1 g, 0.433 mmol, 1 eq) and acetonitrile (5.0 ml) were placed into a 50 mL round bottom flask equipped with a magnetic stir bar and pressure equilising dropping funnel. The solution was cooled using a dry ice bath. Into another 50 mL round bottom flask equipped with a magnatic stirr bar was added pentachlorphenol (0.69 g, 2.598 mmol, 6 eq.) in anhydrous acetonitrile (10 ml). This solution was also cooled in an ice bath. A solution of DIPC (0.109 g, 0.866 mmol, 2 eq) in acetonitrile (5.0 ml) was added to the pentachlorophenol solution and the mixture was stirred at 0° C for 1 h. This reaction mixture was then added to the acetonitrile solution of 5 via the dropping funnel and allowed to react at dry ice temperature for 1 hour and then was placed in the refrigerator (-20° C) and allowed to react over night. The residue in the flask was filtered with a glass filter (porosity 4) and rinsed several times with anhydrous Acetonitrile. The yellowish, amorphous solid was allowed to dry in an dessicator in vacuum for 1 h. The activated monomer 6 obtained with an isolated yield of 62 %. The IR and 1H NMR data for activated monomer 6 is as follows: FTIR (ATR) : 1710, 1696 cm"1 (s;COOH), 1677 cm"1 (COOAr) 1632 cm"1 (s; CO- NH), 1520 cπr1 (s;C=C) Polymerisation of activated monomer 6. The activated monomer 6 ( 0.2 g, 0.275 mmol, 1 eq ) and dichloromethane ( 10 ml) were added to a 50 mL round bottom flask equipped with a magnetic stir bar. The reaction mixture was cooled in an ice bath and a solution of PEGNH2 3'400 ( 0.934 g, 0.275 mmol, 1 eq) in anhydrous 5 dichlormethane (10 ml) was slowly added to the stirred reaction mixture. Aliquots were removed periodically to follow the progress of the reaction. The polyamide 7 was precipitated with five to six times the reaction volume of diethyl ether and rinsed several times with ethylacetate. It was filtered under vacuum with a glass filter (porosity 3) and dried in a dessicator in vacuum. l o Polyamide 7 was also obtained by the direct polymerisation of amino acid aconityl derivative 5.
Monomer 5 (0.5 g, 2.165 mmol, 1 eq), PEGNH2 3'400 and acetonitril (30 ml) were added to a 50 ml round bottom flask. A solution of DIPC (0.545 g, 4.33 mmol, 2 eq) in acetonitrile (10 ml) was added slowly and the reaction was
15 allowed to react overnight at in a temperature of 4 °C. Aliquots were removed every hour to follow the progress of the polymerisation by GPC. The polyamide 7 was precipitated after 24 hours with 5 times the volume of diethylether. The precipitate was filtered under vacuum with a glass filter (porosity 3) and rinsed with ethylacetate before it was dried in a dessicator in vacuum.
20 Example 4
Preparation of polv(amido amine) 11.
To a solution of diamino PEG3400 (2g, 5.96.10-4 mol) and dichloromethane (20 ml) in a 250 ml round bottom flask under nitrogen atmosphere was slowly added over ten minutes a solution of (bromomethyl)methyl anhydride 10
25 (Garman, A.; Kalindjian, S. FEBS Lett. 1987, 223, 361. Deshpande, A.; Natu, A.; Argade, N. J. Org. Chem. 1998, 63, 9557.) (0.15g, 6.10-4 mol) in dichloromethane (1 ml). After 10 minutes, triethylenamine (64 mg, 6.3.10-4 mol). After 1 day the final product was precipitated by addition of ether (150 ml), isolated as powder by filtration and then dried in vacuum. The molecular weight
30 was > 106 g/mol with a polydispersity in the range of 1.5-1.8 (aqueous GPC, PEG standards). Polymer H is a poly(amido amine). Since there is the free carboxylate (C-4) there is an equilibrium with the zwitterionic structure 12.

Claims

Claims
1. A polymer comprising a polymeric backbone comprising at least one unit having the structure (I),
Figure imgf000034_0001
wherein R-R4 comprise groups selected from the group consisting of H, C C12 alkyl, C6-C18 aryl, C7-C18 aralkyl, C6-C18 cycloalkyl or any of the group consisting of CrC12 alkyl, C6-C18 aryl, C7-C18 aralkyl, C6-C18 cycloalkyl substituted, within the carbon chain or appended thereto, with one or more heteroatoms; R and R2 or R and R4 or R and R1 or R2 and R3 may be joined so that with the carbon atom(s) to which they are attached they together form a saturated, partially unsaturated or unsaturated ring system respectively, may have a pendent group which may incorporate a linker unit, (for example a peptide linkage or a unit having the structure (I); A comprises a proton donating moiety selected from the group consisting of
Figure imgf000034_0002
O OH i i I
0=S-OH 0=P-OH
B comprises a hydrolytically labile group and is selected from the group consisting of
Figure imgf000034_0003
wherein each R5 is individually selected from the group consisting of H, C C12 alkyl, C6-C18 aryl, C7-C18 aralkyl, C6-C18 cycloalkyl; wherein groups A and B are in a cis-configuration about bond Ca-Cb; m is an integer of 0 to 100, n, p and q are each an integer of 0 or 1 ; Q comprises 1 or more structures selected from the group consisting of
Figure imgf000035_0001
wherein R6-R11 are individually selected from the same group as defined for group R above and r is an integer between 1 and 5000, and wherein the other components of the polymeric backbone may be other groups having the structure (I), peptide units or degradable polymeric, oligomeric or monomeric units.
2. A polymer according to claim 1 , wherein Ca-Cb is a double bond and p and q are each 0.
3. A polymer according to claim 1 or 2, wherein R, R2 and R3 are selected from the group consisting of hydrogen, methyl, ethyl or propyl, preferably hydrogen.
4. A polymer according to any preceding claim, wherein A is a carboxylic acid group.
5. A polymer according to any preceding claim, wherein B comprises an amide bond.
6. A polymer according to any preceding claim, wherein Q comprises a carbonyl funtionality.
7. A polymer according to any preceding claim, wherein the polymeric backbone additionally comprises polymers selected from the group consisting of acrylic polymers, alkylene polymers, urethane polymers, amide polymers (including polypeptides), polysaccharides and ester polymers.
8. A polymer according to any preceding claim, wherein the polymeric backbone comprises polymers selected from the group consisting of derivatised polyethyleneglycol and copolymers of hydroxyalkyl(meth)acrylamide, most preferably amine derivatised polyethyleneglycol or hydroxypropylmethacrylamide-methacrylic acid copolymers or amide or ester derivatives thereof.
9. A polymer according to any preceding claim, wherein the polymeric backbone comprises the structure (I I)
Figure imgf000036_0001
wherein A, B, Q, R-R4, m, n, p and q are as defined in any preceding claim; L is a polymeric, oligomeric or copolymeric bridging group which comprises polymer selected from the group consisting of acrylic polymers, alkylene polymers, urethane polymers, polyethylene glycols, polyamides, polysaccharides and polyesters; a is an integer of 1 to 100000, b and c are integers of 0 to 100000 and s is an integer of 0 to 100; D comprises one or more structures individually selected from the group consisting of,
Figure imgf000036_0002
wherein R14 and R14' comprise groups individually selected from the same groups as defined for Ror may comprise a structure selected from the group consisting of
Figure imgf000036_0003
wherein n is an integer of 0-100, R15 is selected from the group consisting of hydrogen and C C6 alkyl, R16 to R18 are individually selected from the group consisting of H, C C12 alkyl, C,-C12 alkenyl, C6-C18 aryl, C7-C18 aralkyl, C5-C18 cycloalkyl or is selected from the group consisting of C,-C12 alkyl, C,-C12 alkenyl, C6-C18 aryl, C7-C18 aralkyl, C6-C18 cycloalkyl substituted, within the carbon chain or appended thereto, with one or more heteroatoms, a pendent group comprising a linker unit, for example a peptide linkage or a unit having the structure (I) or a leaving group; R13 is selected from the group consisting of H, C C12 alkyl, C,-C12 alkenyl, C6-C18 aryl, C7-C18 aralkyl, C5-C18 cycloalkyl or is selected from the group consisting of C C12 alkyl, C,-C12 alkenyl, C6-C18 aryl, C7-C18 aralkyl, C6-C18 cycloalkyl substituted, within the carbon chain or appended thereto, with one or more heteroatoms, R13 optionally incorporating a linker unit, for example a peptide linkage or a unit having the structure (I).
10. A polymer according to claim 9, wherein L comprises amine derivatised polyethyleneglycol, most preferably a structure selected from the group consisting of
Figure imgf000037_0001
wherein PEG is polyethyleneglycol, R19-R24 optionally incorporates a pendent group comprising a cleavable linker unit, and may additionally comprise groups individually selected from the same groups as defined for R or may comprise a structure selected from the group consisting of
Figure imgf000037_0002
wherein n and R16 to R18 and R16 to R18 are as defined in claim 9.
11. A polymer according to claim 9 or 10, wherein s is an integer of 1 to 10, preferably 1.
12. A polymer according to claim 9, 10 or 11 , wherein at least one of R14 to R24 incorporates a cleavable bond, preferably a group (i) or one or more peptide bonds.
13. A polymer according to any preceding claim, wherein the polymer is conjugated to a bioactive agent, preferably an anti cancer agent, most preferably, doxorubicin, daunomycin or taxol.
14. A polymer according to any preceding claim, wherein the molecular weight is in the range 0.5kDa-400kDa.
15. A polymer according to any preceding claim, having the structure
Figure imgf000038_0001
wherein PEG is a polyethylene glycol group, or derivative thereof, having a molecular weight in the range 500 Da-100kDa and u is an integer in the range of 1-10000.
16. A polymer according to any of claims 1 to 14, having the structure
Figure imgf000038_0002
wherein PEG is a polyethylene glycol group having a molecular weight in the range 500 Da-100kDa or derivative thereof, and u is an integer in the range of
1-10000.
17. A prepolymer comprising the structure
Figure imgf000038_0003
wherein A, B, Q, R-R3, m, n, p and q are as defined in any preceding claim; R13 and L are as defined in any of claims 9 to 16; A', B', Q' R1,-R4', m', n', p', and q' are selected from the groups as defined for A, B, Q, R1- R4 m, n, p and q respectively; E and K are selected from the group consisting of hydrogen, an activating group or a protecting group and may be the same or different; z is an integer of 1 to 100, y is an integer of 0 to 10 and x is an integer of 0 to
100.
18. A prepolymer according to claim 17, wherein z is 1 , y is 1 and x is 1.
19. A prepolymer according to claim 17 or 18, wherein B and B' comprise a carboxyl group and E and K are selected from the group consisting of hydrogen, N-succinimidyl pentachlorophenyl, pentaflourophenyl, para- nitrophenyl, dinitrophenyl, N-phthalimido, N-norbornyl, cyanomethyl, pyridyl, trichlorotriazine, 5-chloroquinoline, preferably hydrogen or N- succinimidyl.
20. A prepolymer comprising the structure (IV)
Figure imgf000039_0001
wherein A, B, Q, R-R4, m, n, p and q are as defined in any preceding claim; D si as defined in any of claims 9 to 16; G and M are selected from the group consisting of hydrogen, an activating group or a protecting group, i and j are integers of 1 to 10.
21. A prepolymer according to claim 20, wherein i is 1 and j is 1.
22. A prepolymer according to claim 20 or 21 , wherein B and D comprise carboxylic acid groups and G and M are selected from the group consisting of hydrogen, N-succinimidyl pentachlorophenyl, pentaflourophenyl, para-nitrophenyl, dinitrophenyl, N-phthalimido, N- norbornyl, cyanomethyl, pyridyl, trichlorotriazine, 5-chloroquinoline, preferably hydrogen or N-succinimidyl.
23. A process for preparing a polymer, copolymer or prepolymer comprising reacting at least one compound having the structure (V)
Figure imgf000040_0001
wherein R25, R26 and R27 are selected from the group as defined for R; Q" is selected from the group consisting of carboxylic acid, primary or secondary amine carbonyl; u is an integer of 0 or 1 , v is an integer of 1 to 100, R27 and R25 may be attached to form part of a C3 - C12 ring system which may have more than one unsaturated bond and may be aromatic; with at least one compound selected from the group consisting of J and R13LNHR28, wherein L and R13 groups are as defined above and R28 is selected from the same group as defined for R and may be the same or different, J is a compound having at least one primary or secondary amine and a carboxylic acid group and a pendent group incorporating a cleavable bond.
24. A method of selectively degrading a polymer comprising the steps of: a) introducing a polymer as comprising a structure (i) or (I I) as defined in any preceding claim, to an environment having a pH of less than 6.5, b) cleaving said polymer.
25. A method for releasing a bioactive agent comprising the steps of a) introducing a conjugate comprising a structure (I) or (II) as defined in any preceding claim, and a bioactive agent to an environment having a pH of less than 6.5, c) cleaving the bioactive agent from the linker group by acid or enzymic hydrolysis, d) optionally additionally cleaving the polymer by acid or enzymic hydrolysis.
26. A composition comprising at least one polymer as defined in any of claims 1 to 16 and a carrier.
27. A composition comprising at least one polymer as defined in any of claims 1 to 16 and a pharmaceutically acceptable excipient.
28. Use of a polymer as defined in any of claims 1 to 16 as a pharmaceutical excipient.
PCT/US2000/024232 1999-09-03 2000-09-01 Degradable polymers WO2001017515A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00961523A EP1210093A4 (en) 1999-09-03 2000-09-01 Degradable polymers
JP2001521306A JP2003528939A (en) 1999-09-03 2000-09-01 Degradable polymer
AU73464/00A AU7346400A (en) 1999-09-03 2000-09-01 Degradable polymers
US10/069,929 US6828412B1 (en) 1999-09-03 2000-09-01 Degradable polymers

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99307041 1999-09-03
EP99307041.6 1999-09-03

Publications (1)

Publication Number Publication Date
WO2001017515A1 true WO2001017515A1 (en) 2001-03-15

Family

ID=8241608

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/024232 WO2001017515A1 (en) 1999-09-03 2000-09-01 Degradable polymers

Country Status (4)

Country Link
EP (1) EP1210093A4 (en)
JP (1) JP2003528939A (en)
AU (1) AU7346400A (en)
WO (1) WO2001017515A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059973A3 (en) * 2001-12-31 2003-09-18 Polytherics Ltd Block copolymers
WO2006124205A3 (en) * 2005-05-19 2007-04-12 Nitto Denko Corp Hydrophilic polymers with pendant functional groups and method thereof
US7595292B2 (en) 2003-07-11 2009-09-29 Polytherics Limited Conjugated biological molecules and their preparation
US8637022B2 (en) 2008-06-30 2014-01-28 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
US10556989B2 (en) 2015-12-25 2020-02-11 Toray Industries, Inc. End-modified polyamide resin and method for producing same

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2672526T3 (en) * 2008-06-26 2018-06-14 Prolynx Llc Prodrugs and drug-macromolecule conjugates that have controlled drug release rates
CN102088958A (en) 2008-07-10 2011-06-08 艾斯巴技术,爱尔康生物医药研究装置有限责任公司 Methods and compositions for enhanced delivery of macromolecules
US12239713B2 (en) * 2018-03-29 2025-03-04 Nof Corporation Degradable polyethylene glycol conjugate
JP2024097104A (en) * 2021-05-19 2024-07-18 国立大学法人 筑波大学 Poly(ethylene glycol)-b-poly(4-nylon) and nanoparticles thereof

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846380A (en) * 1972-10-31 1974-11-05 M Teranishi Polyamino acid derivatives and compositions containing same
US4745161A (en) * 1985-04-10 1988-05-17 Ceskoslovenska Akademie Ved Soluble and biodegradable polyamino acid activated for bonding of biologically active compound
US5686066A (en) * 1995-10-05 1997-11-11 Mitsui Toatsu Chemicals, Inc. Polyaspartic acid Zwitterionic derivatives, preparation processes thereof, hair-treating compositions and cosmetic compositions
US5817742A (en) * 1994-03-11 1998-10-06 Hoechst Aktiengesellschaft Polymer-conjugated malonic acid derivatives and their use as medicaments and diagnostic agents
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US5898033A (en) * 1995-06-07 1999-04-27 Swadesh; Joel K. Antigen-processing cell-targeted conjugates
US5902812A (en) * 1994-02-14 1999-05-11 Xenova Limited Pharmaceutical piperazine compounds
US5929198A (en) * 1996-07-16 1999-07-27 Nalco Chemical Company Biodegradable poly (amino acid)s, derivatized amino acid polymers and methods for making same
US5935955A (en) * 1994-12-23 1999-08-10 Xenova Limited Pharmaceutical piperazine compounds
US6111057A (en) * 1997-08-08 2000-08-29 Basf Aktiengesellschaft Polymer and process for their production
US6127515A (en) * 1997-11-18 2000-10-03 Aventis Pharmaceuticals Products Inc. Functionalized resin for the synthesis of amides and peptides

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2270920B (en) * 1992-09-25 1997-04-02 Univ Keele Alginate-bioactive agent conjugates

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3846380A (en) * 1972-10-31 1974-11-05 M Teranishi Polyamino acid derivatives and compositions containing same
US4745161A (en) * 1985-04-10 1988-05-17 Ceskoslovenska Akademie Ved Soluble and biodegradable polyamino acid activated for bonding of biologically active compound
US5902812A (en) * 1994-02-14 1999-05-11 Xenova Limited Pharmaceutical piperazine compounds
US5817742A (en) * 1994-03-11 1998-10-06 Hoechst Aktiengesellschaft Polymer-conjugated malonic acid derivatives and their use as medicaments and diagnostic agents
US5935955A (en) * 1994-12-23 1999-08-10 Xenova Limited Pharmaceutical piperazine compounds
US5898033A (en) * 1995-06-07 1999-04-27 Swadesh; Joel K. Antigen-processing cell-targeted conjugates
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
US5686066A (en) * 1995-10-05 1997-11-11 Mitsui Toatsu Chemicals, Inc. Polyaspartic acid Zwitterionic derivatives, preparation processes thereof, hair-treating compositions and cosmetic compositions
US5929198A (en) * 1996-07-16 1999-07-27 Nalco Chemical Company Biodegradable poly (amino acid)s, derivatized amino acid polymers and methods for making same
US6111057A (en) * 1997-08-08 2000-08-29 Basf Aktiengesellschaft Polymer and process for their production
US6127515A (en) * 1997-11-18 2000-10-03 Aventis Pharmaceuticals Products Inc. Functionalized resin for the synthesis of amides and peptides

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1210093A4 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003059973A3 (en) * 2001-12-31 2003-09-18 Polytherics Ltd Block copolymers
US7595292B2 (en) 2003-07-11 2009-09-29 Polytherics Limited Conjugated biological molecules and their preparation
US7939630B2 (en) 2003-07-11 2011-05-10 Polytherics Limited Conjugated biological molecules and their preparation
US8816051B2 (en) 2003-07-11 2014-08-26 Polytherics Limited Conjugated biological molecules and their preparation
US9439974B2 (en) 2003-07-11 2016-09-13 Polytherics Limited Conjugated biological molecules and their preparation
WO2006124205A3 (en) * 2005-05-19 2007-04-12 Nitto Denko Corp Hydrophilic polymers with pendant functional groups and method thereof
US8637022B2 (en) 2008-06-30 2014-01-28 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
US9371525B2 (en) 2008-06-30 2016-06-21 Esbatech, an Alcon Biomedical Reseach Unit LLC Functionalized polypeptides
US10556989B2 (en) 2015-12-25 2020-02-11 Toray Industries, Inc. End-modified polyamide resin and method for producing same

Also Published As

Publication number Publication date
EP1210093A1 (en) 2002-06-05
EP1210093A4 (en) 2005-01-12
JP2003528939A (en) 2003-09-30
AU7346400A (en) 2001-04-10

Similar Documents

Publication Publication Date Title
EP1315777B1 (en) Degradable polyacetal polymers
Yang et al. Penicillin V-conjugated PEG-PAMAM star polymers
ES2404685T3 (en) Heterobifunctional poly (ethylene glycol) derivatives and methods for their preparation
CN104524596B (en) Modified macromolecular
Veronese et al. Bioconjugation in pharmaceutical chemistry
Pechar et al. Poly (ethylene glycol) multiblock copolymer as a carrier of anti-cancer drug doxorubicin
Kurtoglu et al. Drug release characteristics of PAMAM dendrimer–drug conjugates with different linkers
JP4883515B2 (en) Uniform molecular weight polymer
US8802738B2 (en) Polyesters with grafted zwitterions
AU740747B2 (en) Delivery of nucleic acid material to target cells in biological systems
US8119756B2 (en) Hydrolytically degradable polymers and hydrogels made therefrom
Dvořák et al. High-molecular weight HPMA copolymer–adriamycin conjugates
US20030023023A1 (en) Hydrolytically degradable polymers and hydrogels made therefrom
US20070167605A1 (en) Unsaturated poly(ester-amide) biomaterials
US7005123B1 (en) Functional poly-α-amino-acid derivatives useful for the modification of biologically active materials and their application
Zhou et al. Biodegradable polysarcosine with inserted alanine residues: synthesis and enzymolysis
Andersson et al. Poly (ethylene glycol)-poly (ester-carbonate) block copolymers carrying PEG-peptidyl-doxorubicin pendant side chains: synthesis and evaluation as anticancer conjugates
EP1461369A2 (en) Block copolymers
JP4718117B2 (en) PH-sensitive polymer conjugates of anthracycline anticancer drugs for targeted therapy
WO2001017515A1 (en) Degradable polymers
US6828412B1 (en) Degradable polymers
Bulmuş et al. Stimuli-responsive properties of conjugates of N-isopropylacrylamide-co-acrylic acid oligomers with alanine, glycine and serine mono-, di-and tri-peptides
DuBois Clochard et al. Synthesis of soluble polymers for medicine that degrade by intramolecular acid catalysis
Carmali et al. Polyacetals
KR100562895B1 (en) Biologically Active Polymeric Conjugate For Hepatocyte Targeting Of Drug

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 521306

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000961523

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000961523

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10069929

Country of ref document: US

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000961523

Country of ref document: EP